Extended Follow -Up of Argus™ II Sy stem Feasibility Protocol 
Revision O (January 1 5, 2013 ) 
Protocol Title :  Extended Follow -Up of the Argus™ II 
Retinal Stimulation System Feasibility Protocol  
Protocol Number:  CP -003-001-US 
  
Current Revision:  O (January 1 5, 2013)  
  
Sponsor:  Second Sight Medical Products , Inc.  
[ADDRESS_589454] 25, 2010  
March 1, 2010  
 K February 25, 2009  
 J June 17, 2008  
 I Not issued  
 H Not issued  
 G Not issued  
 F 9/7/07  
 E Not issued  
 D 11/22/06  
 C 10/17/06  
 B 8/18/06  
 A 8/8/[ADDRESS_589455] be held confidential and 
maintained in a secure location.  
Do not copy or distribute without written permission.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 2 of 89 
Second Sight Medical Products, Inc.   Company Confidential   Protocol Synopsis 
 
Study Element  Description  
Title:  Extended Follow -Up of Argus II Retinal Stimulation 
System Feasibility Protocol  
Protocol Number:  CP-003-001 
Device:  Argus II Retinal Stimulation Syst em 
Intended Use:  The Argus II Retinal Stimulation System is 
intended to provide electrical stimulation of the 
retina to elicit visual perception in blind subjects 
with severe to profound retinitis pi[INVESTIGATOR_1802].  
Diagnosis and Main 
Criteria for Eligibility:  Retinitis pi[INVESTIGATOR_461043].  
Study Phases:  This study is being conducted in 2 phases:  Investigational phase (i.e. up to 7 years of study 
participation ) and Post -Approval phase (i.e. years 
7-10 of study participation ).  These two study 
phases are summarized on the following pages.  
Sponsor:  Second Sight Medical Products, Inc.  
[ADDRESS_589456], Building 3  
Sylmar, CA [ZIP_CODE]  
+[PHONE_9644] 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 3 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Study Element  Description 
Investigational  Phase:   
Primary Objective:  The obj ective of this feasibility study is to evaluate 
the safety and utility of the Argus II Retinal 
Stimulation System in providing visual function to 
blind subjects with severe to profound retinitis 
pi[INVESTIGATOR_1802].  
Study Design:  Single -armed feasibility study  
Primary Endpoints:  The primary effectiveness endpoint is the subject’s 
visual acuity.  
The primary safety endpoint is the evaluation of 
the safety profile in this population.   
Secondary Endpoint(s):  Secondary endpoints in this study relate to the subject’s ability to perform orientation and 
mobility tasks, their perceived quality of life and ability to undertake activities of daily living.  
Secondary safety endpoints are related to the 
stability of the device and sensitivity of the 
underlying retinal tissue t o electrical stimulation. 
These will be qualitatively evaluated using optical coherence tomography, fluorescein angiography, 
retinal photography, CT scan and perceptual 
thresholds for electrical stimulation over time.  
The set -up, optimization and functiona lity of the 
Argus II System will be evaluated based on the 
tests performed and the feedback from the 
investigators and the subjects.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 4 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Study Element  Description 
Length of Follow -Up:  Subjects initially enrolled in the study for 3 years.  
Following completion of 3 years follow -up, 
subjects may consent to extended follow -up for up 
to an additional 4 years (years 4 -7) in the 
investigational phase and another [ADDRESS_589457].   
 Average length of follow -up in the investigational 
phase will be 5 years, and will range from approximately 3.5 –  5.[ADDRESS_589458] initially enrolled in 
the study.   
Number of Centers:  Up to ten (10) centers within the U.S. 
Number of Subjects:  Up to t wenty  (20) in the U.S.   
  
Study Element  Description  
Post-Approval Phase :  
Post-Approval  Study 
Questions : 1.  Are there any significant changes in the 
device -related adverse events in the late 
follow -up period in subjects i mplanted with the 
Argus II device ?   
2.  What is the long -term reliability of the implant?  
Study Design:  Extending the Single -armed feasibility study  
Study Hypothesis:  There is no study hypothesis  
Study Population: Subjects who have completed participat ion in the 
Investigational Phase of this study and who have 
the Argus II device still implanted are eligible for enrollment in the Post -Approval Phase of this 
study.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 5 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Study Element  Description 
Sample Size:  N=29. Fourteen ( 14) subjects were enrolled in the 
Investigational Phase of the study.  One of these 
[ADDRESS_589459] -approval 
phase of the study.  
Study Endpoints:  The primary endpoint of the post -approval phase 
is safety (i.e. the rates of adverse events).  The secondary endpoint of the post -approval phase 
the long -term reliability of  the Argus II implant.  
Enrollment Plan and 
Follow -up Measures : As with all protocol amendments, IRB approval will be obtained at each site prior to adding the post -
approval phase to the protocol.  
At the completion of the [ADDRESS_589460] the 
option of participating in psychophysical research 
which could occur as frequently as monthly.  
Functional tests at 10 years:  photographic flash, 
square localization, direction of motion and grating 
visual acuity.   
Length of Follow -up: Extend the subjects’ overall participation in the 
study to [ADDRESS_589461] -implant.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 6 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Study Element  Description 
Frequency of Follow -
up Assessments  During year 5 to 7, every six month; from year 8 
to 10 annually. Note the examinations are not 
exactly the same prior to year 7 and thereafter, 
because the study undergoing was extended to 
year 7.  
Statistical Plan: Descriptive statistics will be used to report data collected in the Post -Approval Phase of the study.  
The proportion of subjects experiencing adverse events will be calculated along with the 95% 
confidence intervals.   
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589462] revisions of:  
• Clinician’s Manual (090201)  
• Patient’s Manual (090101)  
• Procedures and Operations Manual (POM) (CP -003-007) 
• Investigator Agreement (CP -003-008) 
• Clinical Trial Agreement  
 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 8 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Table of Contents 
 
1 INTRODUCTION AND RAT IONALE  ......................................................................................................... 12 
2 SYSTEM DESCRIPTION  ............................................................................................................................... 14 
2.1 INTRODUCTION  .............................................................................................................................................. 14 
2.2 PRINCIPLE OF OPERATION  .............................................................................................................................. 14 
2.2.1  Stand- Alone Mode  ............................................................................................................................... 14 
2.2.2  Communication Mode  .......................................................................................................................... 14 
2.3 ARGUS II IMPLANT  ......................................................................................................................................... 15 
2.3.2  Implant Placement  ............................................................................................................................... 16 
2.3.3  Packaging and Sterilization of Argus II Implant  ................................................................................. 17 
2.4 EXTERNAL SYSTEM  ........................................................................................................................................ 17 
2.4.1  Argus II Video Processing Unit (VPU)  ................................................................................................ [ADDRESS_589463]-Operative Medication Regimen (starting on Day 1)  ................................................................... 43 
8 FOLLOW -UP STUDY PROCEDURES  ........................................................................................................ 45 
8.1 CLINICAL FOLLOW -UP ................................................................................................................................... 45 
8.2 ENDPOINT ASSESSMENTS  ............................................................................................................................... 46 
8.2.1  Visual Acuity  ........................................................................................................................................ 46 
8.2.2  Orientation and Mobility T ask ............................................................................................................. 48 
8.2.3  Quality of Life and Activities of Daily Living  ...................................................................................... 48 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 9 of 89 
Second Sight Medical Products, Inc.   Company Confidential  8.2.4  Functional Low Vision Observer -Rated Assessment (FLORA)  ........................................................... 48 
8.2.5  Spatial Vision Tests  .............................................................................................................................. 48 
8.2.6  System Performance ............................................................................................................................ 48 
8.3 ARGUS II SYSTEM FITTING AND PSYCHOPHYSICAL TESTING  ......................................................................... 49 
8.3.1  Argus II System Fitting  ........................................................................................................................ 49 
8.3.2  Psychophysical Testing ........................................................................................................................ 50 
8.3.3  Training and Rehabilitation  ................................................................................................................. 50 
8.4 HOME USE ..................................................................................................................................................... 50 
8.5 EXPLANTATION OF THE IMPLANT  ................................................................................................................... 52 
8.6 REVISION OF THE IMPLANT  ............................................................................................................................ 52 
8.7 MEDICATION REGIME FOR EXPLANT OR REVISION SURGERY  ........................................................................ 53 
8.8 EXTENDED FOLLOW -UP (YEARS 4-10) .......................................................................................................... 54 
9 STUDY COMPLETION  .................................................................................................................................  54 
10 WITHDRAWAL AND REPLA CEMENT OF SUBJECTS  ......................................................................... 55 
11 STATISTICAL METHODS  ........................................................................................................................... 55 
11.1 SAMPLE SIZE ESTIMATE AN D JUSTIFICATION  ............................................................................................ 55 
11.2 ELIGIBILITY OF SUBJECTS , EXCLUSIONS , AND MISSING DATA .................................................................. 55 
11.3 PRIMARY ANALYSIS POPULATION  ............................................................................................................. 56 
11.4 SECONDARY ANALYSIS POPULATION  ........................................................................................................ 56 
11.5 STATISTICAL  ANALYSIS  ............................................................................................................................ 56 
12 DATA MANAGEMENT  .................................................................................................................................  56 
12.1 DATA COLLECTION  ................................................................................................................................... 56 
12.2 DATA PROCESSING  .................................................................................................................................... 57 
13 MONITORING PROCEDURE S .................................................................................................................... 57 
13.1 MONITORING  ............................................................................................................................................. 57 
13.1.1  Site Qualification  ............................................................................................................................ 58 
13.1.2  Site Initiation/Training  .................................................................................................................... 58 
13.1.3  Interim Monitoring .......................................................................................................................... 58 
13.1.4  Site Closure  ..................................................................................................................................... 59 
13.2 DEVICE ACCOUNTABILITY  ........................................................................................................................ 59 
13.3 PROTOCOL VIOLATIONS AND DEVIATIONS  ................................................................................................ 59 
14 ADVERSE EVENTS  ........................................................................................................................................ 59 
14.1 RECORDING ADVERSE EVENTS  ................................................................................................................. 60 
14.1.1  Anticipated Adverse Events  ............................................................................................................. 61 
14.1.2  Anticipated General Adverse Events  ............................................................................................... 64 
14.1.3  Unanticipated Adverse Events  ........................................................................................................ 65 
14.2 REPORTING ADVERSE EVENTS  .................................................................................................................. 65 
14.2.1  Unanticipated, Serious, Device Related Adverse Events  ................................................................ 65 
14.2.2  Serious Adverse Events  ................................................................................................................... 66 
14.2.3  Other Adverse Events Requiring Immediate Notification  ............................................................... 66 
14.2.4  Other Adverse Events  ...................................................................................................................... 66 
14.3 INDEPENDENT MEDICAL SAFETY MONITOR  .............................................................................................. 66 
15 DEVICE FAILURES AND MALFUNCTIONS  ............................................................................................ 66 
16 ETHICAL CONSIDERATIO NS .................................................................................................................... 67 
16.1 DECLARATION OF HELSIN KI ...................................................................................................................... 67 
16.2 ETHICS COMMITTEE /INSTITUTIONAL REVIEW BOARD ............................................................................... 67 
16.3 EMERGENCY ACTIONS ............................................................................................................................... 67 
16.4 INFORMED CONSENT FORM ....................................................................................................................... 67 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589464] RETENTION  .................................................................................................................................  69 
17.4 CRITERIA FOR TERMINATING THE ENTIRE STUDY  ..................................................................................... 69 
17.5 CRITERIA FOR TERMINATING THE STUDY AT AN INVESTIGATIONAL SITE.................................................. 70 
17.6 SPONSOR RESPONSIBILITIES AND COMMITMENTS  ..................................................................................... 70 
17.7 INVESTIGATOR QUALIFICATIONS /RESPONSIBILITIES  ................................................................................. 70 
18 PUBLICATION POLICY  ............................................................................................................................... 70 
APPE NDIX A -  SPONSOR RESPONSIBILI TIES  ................................................................................................ 71 
APPENDIX B -  CLINICAL RISK/BENEFI T ASSESSMENT  ............................................................................. 72 
APPENDIX C -  BIBLIOGRAPHY  .......................................................................................................................... 83 
  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589465]-Explant Schedule  ...................................................................................................................... 34 
Table 5.3  Study Procedures and Tested Eyes  ................................................................................................... 35 
Table 5 .4 Extended Follow -Up Schedule (Years 4 -7) ...................................................................................... [ADDRESS_589466]-Approval Phase Follow -Up Schedule (Years 8 -10) .................................................................. 37 
Table 11.1 Monitoring Visit Schedule  .................................................................................................................. 57 
3.11.1.  Radiofrequency Transmission Standards  .............................................................................................. 79 
 
Table of Fi gures  
 
Figure 2.1  Schematic Overview of the Argus II System  ........................................................................................ 15 
Figure 2.2  Illustration of Argus II Implant ............................................................................................................. 16 
Figure 2.3  Argus II Implant in Position on a Right Eye  (Conceptual Temporal Side View)  ................................ 17 
Figure 2.4  Argus II Video Processing Unit (VPU)  ................................................................................................ 19 
Figure 2.5  Argus II Glasses .................................................................................................................................... 20 
Figure 3.1  Study Flow Chart  .................................................................................................................................. 25 
Figure 6.1  Visual Acuity  Testing at Screening  ...................................................................................................... 41 
Figure 8.1  Visual Acuity Testing at Follow -Up ..................................................................................................... 47 
 
 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 12 of 89 
Second Sight Medical Products, Inc.   Company Confidential  1 Introduction and Rationale  
“In outer retinal degeneration, such as re tinitis pi[INVESTIGATOR_1802] 
(RP), the photoreceptors and their supporting retinal pi[INVESTIGATOR_461044].  In RP (incidence 1:4000) legal 
blindness is reached after 25 years.  In many RP patients over sixty years of age, elementary vision with only gross m ovement 
or bright light perception remains, with little or no appreciable 
peripheral vision.  Eventually, even light perception may 
recede.  Currently, there is no treatment that stops or reverses 
the loss of photoreceptors in retinitis pi[INVESTIGATOR_1802]”.
1 
Traditionally, the approach to vision rehabilitation in subjects with retinitis 
pi[INVESTIGATOR_461045].  If no 
useful vision is achieved, auditory or tactile information is substituted (e.g. 
Braille, cane travel, etc.).  Attempts to remedy or alleviate vision loss have 
been made by [CONTACT_461081], by[CONTACT_461082].  Replacement of 
damaged photoreceptors has been studied in animals through 
transplantation.[ADDRESS_589467] been developed to address the extreme low vision population with retinal degeneration.
3  Electrical 
stimulation at the primary visual cortex has been attempted and has the 
advantage of not requiring a viable optic nerve.4  However, such cortical  
stimulation has its own risks, such as exposing the brain to surgical 
complication and infection.  
Stimulation at more distal neuronal locations has received recent attention and may provide an alternative in an outer retinal degenerative disease such 
as retinitis pi[INVESTIGATOR_1802].
5,6,7,8,9,10,11,12  Electrical stimulation of the optic nerve 
has been used to elicit a sensation of streaks or dots (phosphenes).  Also, electrical stimulation through a contact [CONTACT_461083].  These perceptual 
responses, and the electrically evoked responses recorded from the scalp in 
response to such stimuli, have been interpreted as evidence that inner 
retinal cells in subjects with photoreceptor degeneration retain at least 
partial function.  However, the phosphenes elicited with a contact [CONTACT_461084].  
The production of a small localized visual percept that might allow the 
generation of a two -dimensional array of phosphenes to provide “pi[INVESTIGATOR_461046] -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 13 of 89 
Second Sight Medical Products, Inc.   Company Confidential  visual input” has been explored in both acute and chronic studies of blind 
subjects. Even partial restoration of vision in subjects blind from 
photoreceptor degeneration has been shown to be 
important.13,14,15,16,17,18,19,20,21,22,23,24,25,26  Second Sight has undertaken the 
development of a Retinal Stimulation System intended for use in subjects 
with retinitis pi[INVESTIGATOR_1802].  The earlier generation device (Argus 16 Retinal 
Stimulation System) has been implanted in six subjects in an Investigational 
Study.   The Argus [ADDRESS_589468] the ability 
to perceive phosphenes generated by [CONTACT_14198] -retinal electrical stimuli and 
perform simple tasks such as:  
• Determine the position, orienta tion and direction of motion of objects,  
• Locate doorways   
Based on the results of the study, the current system has incorporated 
several improved features:  
• Increased number of electrodes.  Up to sixty electrodes will be used to increase visual resolution  up to a theoretical limit of 2.1 logMAR based 
on a 575µm spacing of the electrodes.  
• Increased field of view.  The electrodes will cover an area of the retina corresponding to a 20 degree diagonal field of view,  
• Thin Film Electrode Array and cable.  The th in film cable replaces the 
round cable to reduce the risk of conjunctival erosion by [CONTACT_461085].  
• Extra -ocular placement.  The Argus II implant electronics are placed 
on the outer surface of the eye, removing the need for a tunneled 
cable and the implanting of the case  in the skull of the subject.  The 
new implant procedure this affords reduces operative duration significantly and should also reduce post -operative complications.  
This feasibility study will utilize an array with up to sixty independently controllable electrodes implanted epi[INVESTIGATOR_461047], improvement in visual acuity, orientation and mobility, activities of 
daily living, and quality of life in subjects with retinitis pi[INVESTIGATOR_1802].  
 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589469] generation Argus 16.  The main 
differences are that the Argus II provides more independent channels for 
stimulation and that the Argus II Implant (including the Internal Coil) is 
attached to the outside of the eye.  Like the Argus 16 System, the Argus II 
system comprises three sub -system components: the Argus II Impl ant, the 
Video Processing Unit (Argus II VPU) and the Argus II Glasses, and the 
Clinical Fitting System.  The principle of operation and a description of each 
of the Argus II sub -system components (Implant, VPU, and the Clinical 
Fitting System) are provide d below.  
2.2 Principle of Operation 
The principle of operation of the Argus II System is shown schematically in Figure 2.1 .   
2.2.1  Stand -Alone Mode  
In Stand -Alone Mode (inset in Figure 2.1 ), the camera, whic h is attached to 
eye-glasses worn by [CONTACT_423], captures a video image (Argus II Glasses). 
The camera signal is sent to the Argus II VPU (powered by a rechargeable battery), which processes the camera image and transforms it into electrical 
stimulation p atterns. The electrical stimulation data are then sent to the eye -
glasses mounted coil which sends both data and power via radio -frequency 
(RF) telemetry to the Argus II Implant. The implant coil receives the radio -
frequency commands which control an appli cation -specific integrated circuit 
which in turn delivers stimulation to the retina via a n electrode array.  
2.2.[ADDRESS_589470], the Argus I I VPU is connected to a 
dedicated fitting system (Clinical Fitting System), as seen in (Figure 2.1 ) via 
a cable between the VPU and the Communications Adapter.  In this mode, 
computer generated stimuli may be presented to the s ubject and 
programming parameters may be adjusted. In addition, a second computer (Psychophysical Test System) may be utilized to perform more sophisticated 
testing and analysis.  
 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 15 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Figure 2.1  Schematic Overview of the Argus II System  
 
2.3 Argus II Implant  
A diagram of the Argus II Implant is provided in Figure 2.2 .  The implant 
consists of four components:  
1. A small hermetic case that contains the electronics to receive power 
and communicate with the external system, and to drive the electrical 
stimulation of the electrodes. 
2. An internal coil that receives power and data from the external primary coil.   
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589471] by a Watzke sleeve (typi[INVESTIGATOR_461048]), and also by [CONTACT_461086]. The inferior and 
superior implant suture tabs can be seen in Figure 2.3.  Additionally, the 
surgeon may elect to place a suture around the scleral band in the inferior medial quadrant. A description of the surgical implantation procedure is provided in Chapter 3 of the Clinician’s Manual.  
 Electrode cable 
ending in an array  
Internal 
Coil Case Scleral Band  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 17 of 89 
Second Sight Medical Products, Inc.   Company Confidential   
Figure 2.3  Argus II Implant in Position on  a Right Eye  
(Conceptual Temporal Side View ) 
 
 
2.3.3  Packaging and Sterilization of Argus II Implant  
The Argus II implant is individually packaged in a sealed tray with two 
Second Sight retinal tacks and provided sterile. The method of sterilization is 
ethylene oxide and the process has been validated for ocular use.  
2.4 External System  
The External System consists of a pair of glasses with a video camera mounted above the nose pi[INVESTIGATOR_235712] a RF coil that provides power and sends 
and receives data from the implant and the Video Processing Unit.  The 
purpose of the Argus II Video Processing Unit is to convert the input video Array in 
position over 
the fovea  Superior 
suture tabs  
Inferior  
suture tab  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589472] settings  within pre -determined safe limits .  This section describes the 
main components of the Argus II External system.  A detailed description of 
these components is provided in Chapter 2 of the Clinician’s Manual.  
2.4.1  Argus II Video Pro cessing Unit (VPU)  
The Argus II VPU comprises a case, buttons, connectors, rechargeable battery and digital circuit boards.  The buttons are large and shaped so that 
they can be easily identified by [CONTACT_21834].  There is one connector that connects 
the Argus II  VPU to the Argus II Glasses.  The Argus II VPU can also be 
connected to the Argus II Clinical Fitting System during subject testing and fitting using a specialized connector that is covered by a rubber seal when the Argus II VPU is used in stand -alone mode.  An illustration of the Argus II 
VPU is provided in Figure 2.4 . 
 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 19 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Figure 2.4  Argus II Video Processing Unit (VPU)  
 
 
The Argus II VPU is in constant communication with the implant.  The Argus 
II VPU transmits null frame s (containing no stimulation information) until it 
synchronizes with the implant.  Stimulation can then occur.  Any loss of 
synchronization causes an alarm.  
The Argus II VPU acquires video input from the camera and converts it into a digital format.  Filte rs, such as edge detection, may be then applied.  The 
image is then reduced to sixty channel resolution using a downscaling filter.  This representation of the image is then mapped to stimulation intensity 
using customized look -up tables that have been der ived from testing of 
individual subjects.  A check is performed to assure that the overall current and the maximum charge per phase are within safety limits.  The stimulation 
parameters are then sent via telemetry to the implant in frames that employ 
an error detection scheme.  
The Argus II VPU is battery powered and has no “mains” connection.  As will be discussed below, when the Argus II VPU is connected to the Argus II 
Clinical Fitting System, it is optically isolated.  This removes the risk of 
electrical shock that can be associated with medical equipment.  
2.4.[ADDRESS_589473] to house the video camera and radio -frequency system needed to power and 
communicate with the implant.  A photograph of a samp le design of the 
Argus II Glasses is shown in Figure 2.5  below . 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589474] and to allow the external coil assembly to 
be optimally positioned relative to the implant coil to ach ieve a good 
communication link for subjects with different facial structure.  
2.4.3  Argus II Clinical Fitting System  
The Argus II Clinical Fitting System consists of software with a graphical user interface running on a laptop computer.  This computer is connec ted to 
the Argus II VPU using an optically isolated serial connection (Argus II Communication Adapter).  Being optically isolated, the serial connection 
assures that no electric leakage current can flow from the Argus II Clinical 
Fitting System to the Argu s II VPU in the event of a fault condition.   
The Argus II Clinician Fitting System is used to configure the Argus II 
system stimulation parameters and video processing strategies for each 
subject. The fitting application, operating system, laptop, isolation unit and 
Argus II VPU are tested and configuration controlled as a system. The RF board  Coil  Camera  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589475] System is connected to the Argus II Clinicia n Fitting System.  This 
system utilizes MatLAB
® to develop, perform and analyze results of subject 
testing.  During such testing, the safety checks for charge balance, current density and total charge in the Argus II Clinician Fitting System and Argus II 
VPU will continue to operate to protect subject safety.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589476]- approval data in order to monitor the ongoing safety and 
reliability of the Argus II System  
3.2 Study Overview  
The Argus II chronic retinal stimulati on system is an implantable electronic 
device designed to provide chronic electrical stimulation of the retina in 
order to elicit visual percepts in blind subjects with retinitis pi[INVESTIGATOR_1802].   
The Argus II Implant has a theoretical equivalent acuity (or Ny quist limit) of 
approximately 2.[ADDRESS_589477] requires subjects to report the 
orientation of the grating in each trial (horizontal, vertical, oblique left or oblique right).  The vi sual acuity score is defined as the highest level at 
which the subject guesses the orientation correctly at a rate that is half way between chance and perfect performance.  
To facilitate a more targeted screening population, only adults (twenty -five 
years o f age or older) will be evaluated.    
Prior to formal enrollment, subjects will be screened for inclusion by 
[CONTACT_54215] a series of interviews and tests including a complete ophthalmic 
examination, a medical history interview, a psychological evaluation an d 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589478] of th e Argus II system on subjects’ quality 
of life and activities of daily living.  Quality of life will be assessed in all 
subjects using the VisQOL instrument.  The VisQOL is a validated instrument 
for the evaluation of the quality of life in visually impair ed subjects.[ADDRESS_589479]’s 
accuracy and time taken to complete the tasks will be evaluated.  
A functional low -vision observer rated assessment (FLORA) will be 
performed by a certified low vision therapi[INVESTIGATOR_461049]’ everyday lives.  
The implant position, proximity to the retina and the retina under and 
around the array will be evaluated using retinal photography, optical 
coherence tomography (OCT) and fluorescein angiography.   An ultr asound 
B-scan will be obtained to measure the posterior coats thickness in the 
region where the array is placed.  The extra -ocular placement of the device 
will be documented by [CONTACT_3610].  
Subjects may be hospi[INVESTIGATOR_461050].   
Post-operatively, study subjects will be treated and monitored per routine 
hospi[INVESTIGATOR_274724] -operative procedure for ophthalmic surgery.  
Post-operative visits to evaluate and optimize the parameters of the Argus II 
will occur up to twice weekly and will last up to [ADDRESS_589480] it surgically 
removed.   
Following completion of 36 months follow -up, subjects may consent to 
extended follow -up for up to an additional 7  years .  Subjects will be asked to 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 24 of 89 
Second Sight Medical Products, Inc.   Company Confidential  consent for extended follow -up in 3  increments (i.e. years 4 -5, then years 6 -
7, then years 8 -10).  During this time, subjects will be allowed to continue 
using their system and the y will undergo periodic clinical follow -up and 
optional testing in the clinic.  
The device will be explanted if the subject experiences unresolved 
intraocular infection, clinically significant retinal detachment, unexplained or 
known device failure that ma y pose a risk to the subject, or intractable pain. 
All surgically removed devices will be returned to Second Sight for examination.  
This study is designed to enroll up to twenty (20) subjects in the U.S. and 
will require approximately [ADDRESS_589481]’s participation in the study follows in Figure 3.1 below. 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589482] meets 
selection criteria?Document on 
Screening LogExclude From 
Study
Subject signs Baseline 
Informed Consent
(if both a screening and 
main informed consent 
form are being used)Perform Baseline 
Testing and 
ExamsEnroll SubjectDay 0:  
Surgically Implant 
DeviceDay 1 Through 
Month 36:  
Follow-up
Study ConclusionNo
Yes
Subject consents to Years 4-5 
Extended Follow-up?
Years 4-[ADDRESS_589483] consents to Years 6-7
Extended Follow-up?
Years 6-[ADDRESS_589484] consents to Years 8-10
Extended Follow-up?
Years 8-10 Follow-UpYesNo
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589485].  Subjects’ 
visual acuity will be scored according to Table 3.1.  
Effectiveness will be analyzed by [CONTACT_171044]’s visual acuity score at enrollment and at follow -ups after implant.  Control will be  established 
using the subject’s fellow eye and the implanted eye with the device OFF.  
Methods for performing the visual acuity tests are provided in the 
Procedures and Operations Manual.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 27 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Table 3.1  Visual Acuity Scores  
 
Visual Acuity  
log MAR  Snellen  European  
1.6 20/796 6/239 
1.7 20/1002  6/301 
1.8 20/1262  6/379 
1.9 20/1589  6/477 
2.0 20/2000  6/600 
2.1 20/2518  6/755 
2.2 20/3170  6/951 
2.3 20/3991  6/1197  
2.4 20/5024  6/1507  
2.5 20/6325  6/1898  
2.6 20/7962  6/2389  
2.7 20/[ZIP_CODE] 6/3007  
2.8 20/[ZIP_CODE] 6/3786  
2.9 20/[ZIP_CODE] 6/4766  
N/A  Bare Light Perception  
(BLP)  
N/A No Light Perception  
(NLP)  
3.4.2  Primary Safety Endpoint  
The primary safety endpoint is the evaluation of the safety profile in this 
population.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589486]’s time and accuracy will be measured.  This 
instrument will be given to the subject pre -implant, then at prescribed 
intervals post- operatively.  
Subjects’ use of the Argus II System for orientation and mobility in their everyday  lives will be assessed by [CONTACT_10981], certified low -vision 
therapi[INVESTIGATOR_541] (e.g. CLVT, OTR/L, COMS, etc.) using commonly accepted 
techniques for performing such assessment s and a n instrument (Functional 
Low-Vision Observer Rated Assessment [FLORA]) designed specific ally for 
this study.  
Quality of Life and Activities of Daily Living  
These secondary endpoints are the subject’s perceived quality of life and 
ability to undertake activities of daily living.  These endpoints will be 
measured using:  
a) the VisQ OL survey,  
b) the Massof Activity Inventory  
c) Functional Low -Vision Observer Rated Assessment [FLORA] 
(mentioned above)  
The VisQOL Health Survey is a health -related quality of life instrument that 
has been validated and used in low vision subjects.[ADDRESS_589487]- operatively.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589488] finds useful or 
pleasurable, the inventory provides a measure of the “real -world” daily living 
changes, rather than artificial constructs.  This yields a meaningful me asure 
without the risks of the subject “training to the test.”  
Spatial Vision  
Two additional spatial vision tests will be performed to supplement the Grating Visual Acuity  test.  These tests, Square Localization and Direction of 
Motion, are designed to pro vide an objective measure of spatial vision in 
subjects who cannot reach the lowest level of the Grating Acuity scale (2.9 
logMAR).  These tests are similar to  two of the procedures included in the 
Basic Light and Motion (BaLM) test developed by [CONTACT_461087] (U. of 
Freiburg, Freiburg, [LOCATION_013]).   
 
Stability of the Implant  
The stability of the array will be qualitatively evaluated using electrode 
impedances, stimulation thresholds, optical coherence tomography (OCT), 
CT scan and retinal photography.  
System F unctionality  
The set -up, fitting and functionality of the Argus II System will be evaluated 
via psychophysical testing and feedback from the investigators and the subjects via the customer contact [CONTACT_57501].  
3.4.[ADDRESS_589489] -approval phase is safety (i.e. the rates of 
adverse events).  The secondary endpoint of the post -approval phase the 
long-term reliability of the Argus II implant  by [CONTACT_461088] . 
[ADDRESS_589490]:  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589491] a visual 
acuity of Bare Light Perception or worse in both eyes (see Table 3.1).  
NOTE:  The implant should be implanted in the worse -seeing eye.  If 
there is no significant difference in vision between the two eyes, then the investigator will ask the subject which eye is his/her worse eye to 
determine which eye should be implanted.   
2.  Have functional ganglion cells and optic nerve in the implanted eye 
as determined by [CONTACT_461089] a measurable 
electrically evoked response.  
3.  Have a history of useful form vision in the worse -seeing eye.  
4.  Be twenty -five (25) years or older at t he time of enrollment.  
5.  Reside within two (2) hours distance (by [CONTACT_133974]) of the investigational site.  
6.  Be willing and able to comply with the protocol testing and follow -up 
requirements.  
4.[ADDRESS_589492] o r be: 
1. Optic Nerve disease  
a. History of glaucoma  
b. Optic neuropathy or other confirmed damage to optic nerve or 
visual cortex  
2. Diseases or conditions that affect retinal function including but not limited to:  
a. Central retinal artery/vein occlusion (CRAO or CRVO)  
b. End-stage diabetic retinopathy  
c. Retinal detachment or history of retinal detachment  
d. Trauma  
e. Infectious or inflammatory retinal diseases  
3. Diseases or conditions that prevent adequate visualization of the retina including, but not limited to cataract or cornea l degeneration 
that cannot be resolved before baseline testing. Cataracts that permit visualization of the retina are NOT exclusive and will be removed at 
the time of implant surgery. 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589493] to eye rubbing.  
7. Any disease or condition that prevents understanding or 
communication of informed consent, study demands, and testing 
protocols, including: 
a. Cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease  
b. Psychiatric d isease including diagnosed forms of depression 
c. Does not speak a principal language associated with the region 
d. Deafness or selective frequency hearing loss that prevents hearing device alarms and alerts  
8. Pregnancy.  
9. Any metallic or active implantable device (e.g. cochlear implant) in the head.  
10. Conjunctival thinning which may predispose the subject to conjunctival erosion in the area where the implant will be installed 
extra-ocularly (Note:  this is generally associated with a history of 
tobacco use greater than twenty pack -years.
*) 
11. Participating in another investigational drug or device study that may conflict with the objectives, follow -up or testing of this study  
12. Any health concern that makes general anesthesia inadvisable.  
13. Unrealistic expectations of the sy stem.  
14. Known allergy or contraindication to anticipated pre -operative, intra -
operative and post -operative medications.  Refer to Section 7  for a 
description of these medications.  
15. Conditions likely to limit life to less than 1 ye ar from the time of 
screening.  
                                    
*  Pack-years is the number of packs per day times the number of years smoked.   For 
example two packs a day for ten years is 20 pack -years.  Also one pack per day for 15 
years is 15 pack -years.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 32 of 89 
Second Sight Medical Products, Inc.   Company Confidential  16. Diseases or conditions that, in the judgment of the surgeon, impede 
the ability to implant the device or would prevent the system from 
functioning for the duration of the study (e.g. strabismus).  
17. An axial eye length <21.5 mm or >26.0 mm in the implanted eye as measured by [CONTACT_2207].  
 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589494]  
Screening  
(-60 days –  BL) 
Baseline (BL)  
(-60 days – day 
0) 
Implant  
(Day 0)  
1 Day  
(12-36 hours)  
1 Week  
(5-9 days)  
2 Weeks  
(12 – 16 days)  
4 Weeks  
(24- 32 days)  
3 Months  
(75-105 days)  
6 Months  
(170 -200 days)  
9 Months  
(250 – 290 
days)  
12 Months  
(330-390 days)  
18 Months  
(525 -565 days)  
24 Months  
(700 -740 days)  
30 Months  
(890 – 930 
days)  
36 Months  
(1065-1125 
days)  
Informed Consent  x x              
Medical Evaluation  x† x  x x x x x x x x x x x x 
Psychological Evaluation  x               
Complete Eye Exam  x    x x x x x x x x x x x x 
Visual Field   x       x  x  x  x 
Retinal Photography   x   x  x x x x x x x x x 
Fluorescein Angiogram   x   x  x x x x x x x x x 
Optical Coherence Tomography   x   x  x x x x x x x x x 
Ultrasound A - and B -scans  x      x (B- 
only) If subject was enrolled before March 2010, B -scan 
should be performed at next available clinic visit.  
CT Scan      x           
Document F ixation Position and Eye Movement Range   x   Performed on an as -needed basis.  
Visual Acuity, including  
   Grating Acuity  
   Full Field Stimulus Threshold  
   (Electrically Evoked Response (EER)‡ X§       x x  
x x x  
x 
Orientation and Mobility Tasks   x      x x  x x x  x 
Massof Activity Inventory   x      x x  x x x  x 
VisQOL   x      x x  x x x  x 
Functional Low -Vision Observer Rated Assessment (FLORA)            X***    X*** 
Square Localization & Direction of Motion   x      x x  x x x  x 
Perceptual Thre sholds for Electrical Stimulation        x x x  x x x  x 
System Fitting and Psychophysical Testing      Ongoing. **  Typi[INVESTIGATOR_897] 1 -2 times per week.  
Home Use      Ongoing after subjects meets home use criteria.  
                                    
† If the subject is female and capable of giving birth, this evaluation must include a pregnancy test  
‡ EER is only performed at screening a nd only if the subject has no light perception  
§ These tests are to be performed twice, on different days  
** Testing commences at latter of the following:  (a) [ADDRESS_589495]- implant, or (2) when the conjunctiva is sufficiently healed in the opi[INVESTIGATOR_461051]. 
*** For subjects enrolled in the study prior to August 2010, the FLORA should be performed as soon as possible after the subject consents to the test.  The 
assessment will be counted toward the closest follow -up visit (i.e. 1 or 3 years) even if it is performed outside that visit window.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589496]  Explant 
(Day 0)  1 Day  
(12-36 
hours)  1 Week  
(5-9 
days)  4 Weeks  
(24- 32 
days)  3 Months 
(80-100 
days)  6 Months 
(170 -200 
days)  12 Months 
(340 -380 
days)  
Medical Interview, 
Complete Eye exam and 
Review for AE   X X X X X X 
Retinal Photography    X X X X X 
Optical Coherence 
Tomography    X X X X X 
Fluorescein Angiogram    X X X X X 
The post –explant schedule should be followed ONLY in the event that the device is explanted and the 
subject consents to post -explant follow -up.  Unless otherwise indicated, the device will remain implanted 
at the conclusion of the study.  
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589497]  Screening & Baseline  Follow-up  
Eye Tested  Eye Tested  System ON/OFF  
Complete Eye Exam   Both, separately  Both, separately  OFF 
Visual Field  Both, sep arately  System OFF - Both, 
separately  
System ON –  Both, 
together  ON and OFF  
Retinal Photography  Both, separately  Both, separately  OFF 
Fluorescein Angiogram  Both, together  Both, together  OFF 
Optical Coherence Tomography  Both, separately  Both, separate ly OFF 
Ultraso und A- and B -scan s Both, separately  N/A N/A 
CT Scan  N/A Implanted only  OFF 
Document Fixation Position and Eye 
Movement Range  Both, together  Both, together  OFF 
Visual Acuity Tests     
Grating Acuity  Both, separately  Both, separately  ON and  OFF 
Full Field Stimulus Threshold  Both, separately  Both, separately  OFF 
Electrically Evoked Response  Implanted only  N/A N/A 
Orientation & Mobility Tasks  Both, together  Both, together  ON and OFF  
Massof Activity Inventory  N/A N/A N/A 
VisQOL N/A N/A N/A 
Square Localization & Direction of 
Motion Test  Both, together  Both, together  ON and OFF  
Perceptual Thresholds for Electrical 
Stimulation  N/A Implanted Only  ON 
FLORA  N/A Both, together  ON and OFF  
 
Extended Follow -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page 36 of 89 
Second Sight Medical Products, Inc.   Company Confidential   
Table 5.4  Extended Follow -Up Schedule (Years 4 -7) 
 
Evaluation or Test  Enrollment  in 
Years 4- 5 
Extended 
Follow -up 
 
(After 36 Month 
follow -up) 3.5 Years 
 
(40.5 – 
43.5 
Months)  4 Years 
 
(46.5 – 
49.5 
Months)  4.5 Years 
 
(52.5 – 
55.5 
Months)  5 Years 
 
(58.5 – 
61.5 
Months)  Enrollment  
in Years 6- 7 
Extended 
Follow -up 
 
(After 5 Year 
follow -up) 5.5 Years 
 
(64.5 – 
67.5 
Months)  6 Years 
 
(70.5 – 
73.5 
Months)  6.5 Years 
 
(76.5 – 
79.5 
Months)  7 Years 
 
(82.5 – 
85.5 
Months)  
Informed Consent  x     x     
Medical Follow -Up, including:  
Complete Eye Exam  
Current Medical Status 
Adverse Events   x x x x  x x x x 
Retinal Photography    x  x      
Optical Coherence Tomography    x  x      
Visual Function 
Full-Field Stimulus Threshold (FST)*  
Photographic flash test  
Grating Visual Acuity 
Square Localization  
Direction of Motion   x  x  
    
Orientati on and Mobility Tasks   x  x      
Massof Activity Inventory   x  x      
Functional Low -Vision Observer Rate 
Assessment (FLORA)   If not performed in years [ADDRESS_589498] and investigator.   
May occur as frequently as 1x/week, but usually occurs no more than 1x/month.  
Home Use  Optional at the discretion of the subject.  Ongoing.  
* FST is only required at those centers that have a Diagnosys Espi[INVESTIGATOR_461052] -Up of Argus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589499]-Approval Phase  Follow -Up Schedule (Years 8 -10) 
 
Evaluation or Test  Enrollment  in Years 8-
10 Extended Follow -up 
 
(After 7 Year  follow -up) 8 Years 
 
(± 1.5 Mo ) 9 Years 
 
(± 1.5 Mo ) 10 Years 
 
(± 1.5 Mo ) 
Informed Consent  x    
Medical Follow -Up, including:  
Complete Eye Exam  
Current Medical Status 
Adverse Events   x x x 
Photographic Flash*     x 
Square Localization Test*     x 
Direction of Motion Test*     x 
Grating Visual Acuity*     x 
Perceptual Thresholds for Electrical Stimulation*   x x x 
Transfer VPU data to sponsor *  x x x 
System Fitting and Psychophysical Testing*  Option al at the joint discretion of subject and investigator.   
May occur as frequently as 1x/week, but usually occurs no more than 1x/month.  
Home Use  Optional at the discretion of the subject.  Ongoing.  
 
* These tests are only required for subjects who are us ing the System at home.  
.
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589500] selection criteria after screening will be asked to review and sign a second Informed Consent Document (the Baseline Informed 
Consent Form) prior to beginning participation in the study.  
6.1.3  Screening  Tests and Exams  
Screening consists of the following tests and exams:  
1. Medical Evaluation  
This evaluation is performed to: 
a. Evaluate the subject’s expectations of the system   
b. Review the subject’s ophthalmic history and records  
c. Review the subject’s general medical history  
d. If the subject is female and is capable of becoming pregnant, administer a pregnancy test to ensure the 
subject is not pregnant.   Also, advise the subject of 
appropriate birth control measures that must be maintained during the course of the study.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589501]’s chronic and acute medications  
2. Psychological Evaluation  
This evaluation is performed to confirm that the subject:  
a. Seeks participation in the study primarily to contribute to 
the development of effective retinal prosthes is technology, 
rather than with the expectation of a substantial improvement in his or her level of vision, and is willing and 
able to commit to a lengthy rehabilitation process with 
limited benefits.  
b. Does not have any underlying psychological condition that would impede the study evaluations and follow -up such as:   
i. Cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease  
ii. Psychiatric Disease including diagnosed forms of depression 
3. Complete Eye Exam  
4. Ultrasound A-  and B -Scans 
An ultrasound A- scan is performed to determine the axial length of 
the eyes.   A B-scan is performed to determine the posterior coats 
thickness (i.e. the retina, sclera, choroid complex ) in the region 
where the array will be implanted.  
5. Visual Acuity Tes ting  
Visual acuity testing will be performed at screening to confirm that the subject meets the first two inclusion criteria:   
1.  Have a confirmed history of retinitis pi[INVESTIGATOR_461053] a visual acuity of Bare Light Perception or worse in both eyes.  
2.  Have fun ctional ganglion cells and optic nerve in the 
implanted eye as determined by [CONTACT_461090] a measurable electrically evoked response.  
Refer to Figure 6.[ADDRESS_589502], a vis ual 
acuity score will be assigned for each eye using Figure 6.1  and 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589503] visual score measured from the two days of screening 
tests will be used as the baseline value.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589504] eye 
(each eye is tested separately)Perform Grating 
Acuity Test
Is subject’s acuity 2.9 logMAR or better? Exclude subject. Yes
Perform Full Field Stimulus 
Threshold Test (FST)
Perform Electrically Evoked 
Response Test
(Only performed in eye 
intended for implant)Subject meets visual acuity criteria for this eye. 
Classify visual acuity of eye as Bare Light PerceptionSubject perceives 
light in all FST test 
runs?Yes
Subject perceives 
light?
No
Exclude subject. No
Repeat Process in Other EyeNOTE:  Subject 
must be meet the 
visual acuity 
criteria in both eyes 
on [ADDRESS_589505] 9/20 blocks?YesIf FST does not use a Xenon 
Flash, Perform Photographic 
Flash Detection Test
No
 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589506] numbers contain the prefix of the site 
number to allow unique identification.  
6.3 Baseline Testing  
Baseline testing consists of the following:  
1. Medical Evaluation.  
2. Visual Field  
3. Retinal Photography  
4. Fluorescein angiogram (FA)  
5. Optical Coherence Tomography (OCT)  
6. Documentation of Fixation Position and Eye Movement Range  
7. Orientation and mobility tasks  
8. Massof Activity Inventory questionnaire  
9. VisQOL questionnaire  
10. Square Localization and Direction of Motion tests  
 
Baseline testing may r eveal that a subject no longer meets the subject 
selection criteria (e.g. imaging reveals that the subject has a condition that 
could prevent the system from functioning for the duration of the study).  In 
this situation, the subject would be withdrawn fro m the study.  Refer to 
Section [ADDRESS_589507] withdrawal.  
 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 43 of 89 
Second Sight Medical Products, Inc.   Company Confidential  7 Peri- Operative Study Procedures  
7.1 Pre-Operative Medication Regimen  
Subjects will be treated pre -operatively with Ciprofloxacin (or an equivalent 
dosage of another quinolone family antibiotic) 500mg BID for 48 hours 
before implant.  
7.2 Argus II Retinal Prosthesis Implantation 
Refer to the Clinician’s Manual, Chapter 3 (Surgical Procedures) for instructions for how to implant the Argus II Retinal Prosthesis, including 
intra-operative medic ations.   
If there is a significant difference in vision between the two eyes, the device should be implanted in the worse eye.  This decision will be made by [CONTACT_984], in consultation with the subject, as necessary. 
If the subject is phakic in the ey e intended for implant, the lens will removed 
at the beginning of the implant procedure to either remove an existing 
cataract or prevent the formation or progression of a cataract during follow -
up which could impair the ability to visualize the implant and the retina.  
The day of implant is considered Day 0.  
7.2.[ADDRESS_589508]-Operative Medication Regimen (starting on Day 1)  
 
1. Antibiotics  
o Ciprofloxacin:  500mg BID for 14 days  
o Gatifloxacin (Zymar) eye drops:  [ADDRESS_589509] 14 days 
 
2. Steroids  
o Prednisolone 60mg dail y PO for two weeks, immediately followed by a 
Methylprednisolone (Medrol) taper pack (8mg), until the pack is 
completed  
o If Medrol pack is unavailable, reduce Prednisolone by 10mg 
per day  
o Pred Forte 1% –  1 drop QID for 2 weeks.  Continue prn.  
 
NOTE:  If th e subject experiences low intraocular pressure (IOP) post -
operatively, then the steroid regimen should be as follows:  
 o Halve the oral Prednisolone dose if IOP mmHg reaches 5 or less 
o Reduce Pred Forte 1% to 1 drop daily  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 44 of 89 
Second Sight Medical Products, Inc.   Company Confidential  o Once IOP has reached 10 mmHg or highe r, increase the oral 
Prednisolone dose as clinically indicated  
o Continue Pred Forte drops as clinically indicated 
 
3. Mydriatics  
o 1 drop topi[INVESTIGATOR_461054] 1% once daily for 2 weeks  
 
NOTE 1:  Investigators should direct  subjects taking chronic or acute 
medication to make their primary  physician aware of the 
medications anticipated for pre and post management of the 
implant and that these may affect their pre -existing medical 
conditions and/or interact with the medications they are taking.     
NOTE 2:  Modifications to the medication regime should be made where 
necessary to optimize subject care.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 45 of 89 
Second Sight Medical Products, Inc.   Company Confidential  8 Follow -Up Study Procedures  
Postoperative follow -up provides the data necessary to monitor system 
safety, including medical/surgical risks or complications and adverse events, 
and to monitor system effectiveness over time. Subjects will be followed 
post-operatively for 36 months. At the end of 36 months, subjects will be 
offered the opportunity to extend their follow -up for up to an additional 7  
years  (Refer to Section 8.8 , Extended Follow -Up (Years 4 -10)). 
The schedule of observations and assessments to take place during follow -
up and the appropriate time intervals during which each visit should occur 
are summarized in Table 5.1.  Postoperative evaluations are counted from 
the date of the surgery, with the day of surgery being Day 0.  
To determine which eye should be tested during follow -up, refer to Table 
5.3.  Methodologies for clinical follow -up, endpoint testing procedures , and 
certain system fitting and psychophysical testing procedures are detailed in 
the Procedures and Operations Manual.  
8.1 Clinical Follow -Up 
Clinical follow -up consists of the following:  
1. Medical Evaluation, including a review for adverse events, current  
medications and other relevant clinical findings  
2. Complete eye exam  
3. Visual Field  
4. Retinal photography  
5. Fluorescein angiography  
6. Optical coherence tomography (OCT)  
7. Ultrasound B -scan – If the subject was enrolled prior to March 2010, 
this test should be perform ed at the next available clinic visit.  
8. CT-Scan 
9. Documentation of Fixation Position and Eye Movement Range –  This 
is only performed on an as -needed basis.  
If a portion of the subject’s implant array overlaps the optic nerve head, 
clinicians should carefully monitor the optic nerve head during the follow -up 
eye exams and review serial photographs from retinal photography, fluorescein angiography and OCT to confirm that the array is a safe distance 
from the optic nerve head surface and does not appear to be damaging this 
structure.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 46 of 89 
Second Sight Medical Products, Inc.   Company Confidential  8.2 Endpoint Assessments 
8.2.1  Visual Acuity  
Follow -up visual acuity testing should be performed and scored according to 
Figure 8.1.   
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589510] (and 
Photographic Flash 
Detection, if applicable)
Was eye assigned a 
logMAR score of 2.[ADDRESS_589511]?Assign this score 
as the eye’s Visual 
Acuity.Yes
No
Did subject perceive light with 
the Full Field Stimulus 
Threshold Test or Photographic 
Flash Test?YesScore eye as Bare 
Light Perception
No
Score eye as 
No Light 
Perception
 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589512] has been successfully fitted with the external system (i.e. 
the subject’s VPU has been loaded with a Video Config uration File), the 
subject will be asked to perform the orientation and mobility tasks per the schedule in Table 5.1.  
8.2.[ADDRESS_589513].  
8.2.4  Functional Low Vision Observer -Rated Assessment  
(FLORA)  
This assessment will be performed at [ADDRESS_589514] required follow -up visit (i.e. 1 or 3 years) even if it is 
performed outside that test window.   
8.2.[ADDRESS_589515] per the 
schedule in Table 5.1.  
8.2.6  System Performance  
System performance will be evaluated using two measures:  
• Electrode impedance will be  recorded to ensure continued function of 
the electrodes in the array. Electrode impedance measurements will be taken at the beginning and, if possible, at the end of eac h testing 
session.  
• Perceptual Thresholds for Electrical Stimulation will be recorded to 
document the level at which electrical stimulation produces a 
phosphene (the perception of a spot of light). Threshold testing will be 
performed according to the schedule in Table 5.1.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 49 of 89 
Second Sight Medical Products, Inc.   Company Confidential  8.3 Argus II System Fitting and Psychophysical Testing  
Subjects will be scheduled for fitting and psychophysical testing sessions up 
to twice weekly, with sessions lasting up to four (4) hours.  A Second Sight 
Field Clinical Engineer may assis t the investigator during these test sessions.  
8.3.[ADDRESS_589516] effective Visual 
Processing Unit (VPU) settings for subjects implanted with a retinal 
prosthesis.  Psychophysical testing will be used to establish the electrical 
pulse parameters for stimulating retinal neurons and to determine the optimal method for transforming the video input signal to a useful pattern of 
electrical stimulation.  
The procedure for converting video camera input  to a pattern of electrical 
stimulation can be broken down into two general parts: the video chain and 
the Video Configuration File (VCF).  
The Video Chain  
The image is captured by a video camera mounted on the glasses. This video 
image is sent to the VPU,  where the video input signal is processed by a 
series of digital filters. The goal of these operations is to construct the inferred “neural image” best suited for presentation to the retinal circuitry through electrical stimulation. The image should consi st of intensity values 
that are scaled to maximize the dynamic range for perceived brightness.  
Video Configuration File (VCF)  
The Video Configuration File specifies the method for converting the output of the video chain to electrode stimulation values. Th e perceptual brightness 
produced by [CONTACT_461091], such as the pulse amplitude. The VCF contains a look -up 
table that specifies the mappi[INVESTIGATOR_461055]. The file also specifies which spatial sections 
of the video image are sent to each electrode.  
Constructing the Video Configuration File  
The video configuration file will be constructed based on measurements of the percepts produced by [CONTACT_461092]. The experimental 
data required to construct a video configuration file may vary from subject to subject, and the design and execution of these experiments is referred to as fitting. During the course of this feasibility stud y, we will refine and 
evaluate our fitting procedures to determine the most efficient and effective method of optimizing system parameters.  
Video Configuration File Refinement 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589517]’s perception.  For 
example, if a subject’s performance is hindered by [CONTACT_461093], the frequency of stimulation may be increased.  
8.3.[ADDRESS_589518] various non -
invasive objective tests (“psychophysical testing”) to monitor the progress of the fitting procedure and to determine the most appropriate testing to 
optimize system parameters. The specific psychophysical tests to be 
performed may  vary from subject -to-subject and additional tests will be 
developed as the study progresses.  Results will be summarized in the annual report.  
8.3.[ADDRESS_589519] during the weekly System 
Fitting and Psychophysical Testing Sessions at the clinic.  Subjects may also receive some vision rehabilitation to enhance their ability to receive benefit 
from the Argus II System.  Qu alified vision rehabilitation specialists (e .g. 
CLVT, OT R/L, COMS, etc.)  may assist with this training and r ehabilitation.  
At the discretion of the investigator and with the agreement of the subject, a 
certain amount of training and rehabilitation may tak e place at the subject’s 
home and/or immediate environs or in an environment outside of the clinic.  
8.4 Home Use  
As soon as possible after implant, subjects will be trained to use the Argus II 
system at home. After meeting the requirements for home use (see below), 
they will be allowed to take their system home and will be instructed to use 
it for approximately 4 hours/day, [ADDRESS_589520] and caregiver (if applicable) are instructed that the system may not 
be used as the primary mechanism for mobili ty. 
Subjects will report the details of their home use to the investigator during 
their fitting and testing sessions.  
Criteria for Home Use  
Before being allowed to use the Argus II System at home, subjects must 
demonstrate the ability to set- up and use the system and respond to audible 
alarm states without trainer intervention.   In addition, the subjects and their caregivers (if applicable) will be provided with a Patient’s Manual (hard 
copy and audio version) for information regarding the operation the A rgus II 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 51 of 89 
Second Sight Medical Products, Inc.   Company Confidential  system. Subjects and their caregivers (if applicable) will be specifically 
trained on the following:  
1. System Set -up and Operation  
1.1. The Patient Manual will be used to instruct the subject to set-
up and operate the system.     
1.2. The Patient Manual will be used to review all safety information related to the system, including the Warnings and Precautions 
section, the significance of audible alerts and how to respond to 
them, any Caution statements that are included throughout the 
manual, and how to troubl eshoot problems.   
2. “Real World” Training  
2.1. Tasks, such as the ones listed below, will be used to familiarize 
the subject with operation of the system in real world 
environments.  
a. Identify and localize a combination of fluorescent lights that 
are switched on a nd off.  
b. Identify the locations of doors or windows.  
c. Find the position of a dark colored chair against a white 
background.  
d. Identify whether a person passed by [CONTACT_461094]. 
Equipment for Home Use  
Each subject will be furnish ed with the following:  
1. Argus II Video processing unit  
2. Argus II Glasses 
3. Argus II VPU Pouch to hold the Argus II VPU.  
4. Two Argus II VPU Batteries.  
5. Argus II VPU Battery Charger.  
6. Argus II Traveling Case.  
7. Patient User manual (hardcopy and audio version).  
8. Tactile  targets to practice using the system.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 52 of 89 
Second Sight Medical Products, Inc.   Company Confidential  8.5 Explantation of the Implant  
The Argus II implant will be explanted at any time during the study (i.e. 
either during the initial 36 month follow -up period or during extended follow -
up in years 4 -10) if any of the foll owing conditions occur:  
1. Subject requests explant either upon study termination or subject 
withdrawal.  
2. Device becomes compromised in any way that compromises the subject’s safety.  
3. Unresolved infection.  
4. Clinically significant retinal detachment that does not respond to 
treatment.  
5. Unexplained device failure that places the subject at risk.  
6. Intractable pain.  
All surgically removed devices will be returned to Second Sight for analysis.  Second Sight will provide a procedure for treatment and shippi[INVESTIGATOR_461056].  
Subjects will be followed post -explant per the schedule in Table 5.[ADDRESS_589521] withdrawn from study and refuse further follow -up. 
Refer to the Clinician’s Manual, Chapter 3 (Surgical Procedures) for instruction s for how to surgically remove the Argus II Retinal Prosthesis.  
The pre -, Intra -Op and Post -Explant medication regimen is provided below 
(Section 8.7).  
8.6 Revision of the Implant  
The position of the Argus II implant may be revi sed during the study to 
address a variety of situations including, but not limited to:  
1. Correct the position of the implant due to movement.  
2. Reposition extra -ocular parts of the implant to improve functionality of 
the system.  
The revision may include replac ing or adding materials that were used in the 
original surgery to better secure the implant (i.e. sutures and metal tacks).  
The decision to revise an implant will be made by [CONTACT_11065], in 
consultation with the Second Sight.  The procedure for performing  the 
revision surgery will vary from subject -to-subject.  It is recommended that 
the surgeon consult with Second Sight as to how to perform the revision 
surgery.  The pre -, Intra -Op and Post -revisions surgery medication regimen 
is provided below (Section 8.7 ). 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589522] -revision surgery.  
8.7 Medication Regime for Explant or Revision Surgery  
Pre-Surgical 
Two days (48 hours) prior to the planned surgery, start the subject on 
Ciprofloxacin (or an equivalent dosage of another quinolone antibiotic) 500mg BID.  
Intra -Operative  
Intra-operative medications should follow the same regime as for the initial 
surgery.  
Post-Operative (starting the day after surgery)  
 
1. Antibio tics 
o Ciprofloxacin:  500mg BID for 14 days  
o Gatifloxacin (Zymar) eye drops:  [ADDRESS_589523] 14 days 
 
2. Steroids - Steroids should be prescribed according to clinician 
judgment.  Oral s teroids are not required for subjects whose device is 
explante d.  Below is a potential regime for consideration.  
 
o Prednisolone 60mg daily PO for up to two weeks, immediately followed by a Methylprednisolone (Medrol) taper pack (8mg), until 
the pack is completed.   
o If Medrol pack is unavailable, reduce Prednisolone by  10mg 
per day  
 
NOTE:  The requirement for and duration of oral steroids should be 
adjusted based on the duration and nature of the surgery. The full 
fourteen days of oral steroids should be administered before 
tapering in cases where the surgery is extens ive and/or involves 
manipulation of the extra -ocular parts of the device.  
 
o Pred Forte 1% –  1 drop QID for 2 weeks.  Continue prn.  
 
NOTE:  If the subject experiences low intraocular pressure (IOP) post -
operatively, then the steroid regimen should be as foll ows: 
 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 54 of 89 
Second Sight Medical Products, Inc.   Company Confidential  o Halve the oral Prednisolone dose if IOP mmHg reaches 5 or less 
o Reduce Pred Forte 1% to 1 drop daily  
o Once IOP has reached 10 mmHg or higher, increase the oral 
Prednisolone dose as clinically indicated  
o Continue Pred Forte drops as clinically indicated 
 
3. Mydriatics  
o 1 drop topi[INVESTIGATOR_461054] 1% once daily for 2 weeks  
8.8 Extended Follow -Up (Years 4 -10) 
Following completion of the 36 months follow -up, subjects will be offered the 
opportunity to extend their participation in the study for up to an additional 7 years , to provide a maximum follow -up duration of 10 years .  Subjects still 
implanted with the Argus II device will be asked to consent for extended 
follow -up in the following increments:  
• Years 4 -5 
• Years 6 -7 
• Years 8 -10  
If subjects consent to extend their follow -up, they may continue to use the 
Argus II System at home and they will be required to undergo clinical follow -
up.  During the extended follow -up period, testing in the clinic (i.e. 
psychophysical testing and system fitting ) will be optional and will be 
scheduled at the joint discretion of the subject and investigator.  The 
schedule for the extended follow -up for years 4 -7 is provided in Table  5.4 
(page 36).  The schedule for the extended follow -up for years 8 -10 is 
provided in Table 5.5 (page 37). 
[ADDRESS_589524] -implant  (if the subject does not 
consent to extended follow -up), or through 5, 7, or [ADDRESS_589525] -implant (if 
they consent to extended follow -up), at the time of withdrawal, or [ADDRESS_589526]/ethics committee approval.  
The study will be complete when all subjects have completed the study.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589527] her/him.  In any circumstance, every effort must be made to 
document subject outcome, if possible.  
If the subject becomes pregnant, she must be withdrawn from the study. Such subjects may elect to rejoin the study at the completion of pregnancy 
and lactation if the study is still open.  
In all cases, the reasons for withdrawal must be recorded on the case report 
form and in the subject’s medical records.  If possible, a complete, final 
examination should be performed on all subjects who intend to withdraw 
from the study.  
If the Argus II Implant  is explanted, the subject will be followed post-
surgery for twelve months to allow evaluation of adverse events related to the explant procedure unless they have withdrawn and refuse further follow -
up. 
Any subject who has been implanted with the study dev ice and withdrawn 
from the study will not be replaced. Subjects withdrawn prior to implant may be replaced.  
11 Statistical Methods  
11.1  Sample Size Estimate and Justification 
As the objective of the study is to evaluate the safety of the implanted system and the u tility of the study measures in this population, a maximum 
of twenty (20) subjects are to be enrolled in this feasibility study in the U.S.  
This number of subjects will allow evaluation of the basic performance of the 
system, an estimate of the level of vision provided and the safety profile of 
the system in the specified patient population.   
11.2  Eligibility of Subjects, Exclusions, and Missing Data  
All subjects enrolled according to the entry criteria in Section 4  will be 
eligible  for evaluation, regardless of the sequence of treatment that ensues.  
All subjects enrolled in the study are considered eligible for follow -up and 
will be required to adhere to the follow -up schedule outlined in Table 5.1 and 
Table 5.2 . 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 56 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Management of dropouts and missing data will depend on their frequency 
and the nature of the outcome measure.  Adjustments for missing data will 
be performed only if deemed necessary and will be described completely.   
Outlier values will be eva luated for their validity; all data will be included 
unless judged to be invalid.  
11.[ADDRESS_589528] of subjects on an “as treated” basis.  
11.[ADDRESS_589529] demographics, clinical history, risk factors, preoperative, and procedure data will be summarized using descriptive statistics for continuous 
variables (e.g. mean, standard deviation ) and frequency tables or 
proportions for discrete variables.   
Post-procedure information will be collected at regularly scheduled follow -up 
examinations according to the clinical study schedule.  Estimates of primary and secondary endpoints will be repor ted along with their 95% confidence 
intervals.  The Kaplan -Meier product limit method will be used to determine 
rates of events for time -to-event endpoints such as retinal detachment.  
Where testing is conducted with the system on and off, comparison will be 
made between subject performance under both conditions.  Where testing is 
conducted with the implanted and non- implanted eyes separately, 
comparison will be made between subject performances using each eye.  
12 Data Management  
12.1  Data Collection  
Case Report Forms (CRF) are required and must be completed in black or 
blue ink for each subject enrolled. The authorized site representative signs 
and dates the case report form s on the specified pages to assure the 
accuracy and completeness of the recorded data.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589530] 
Operating Procedures.  Audits may be performed for quali ty assurance of 
data handling.  
13 Monitoring Procedures  
Second Sight Medical Products, Inc will be the study monitor.  
13.1  Monitoring  
Second Sight personnel will monitor all clinical studies in a manner 
consistent with applicable health authority regulations and the clinical 
research standards adopted by [CONTACT_461095]. Site monitoring includes a site qualification visit, initiation/training visit, interim monitoring visits, and a 
study closure visit.  Monitoring visits will occur according to the schedule in 
table 11.[ADDRESS_589531] to accuracy and completion of data and compliance to the protocol. 
Table 11.1 Monitoring Visit Schedule  
Monitoring Visit  Number 
of Vis its Frequency  Timing  
Qualification  1 Once Before IRB 
submission.  
Initiation/Training  [ADDRESS_589532] 
enrollment.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589533] population, clinical facilities/equipment and the adequacy of the 
investigator and additional staff’s credentials, availability and resources to 
conduct the study.   
13.1.2 Site Initiation/Training  
A site initiation/training visit will be performed to train the investigational 
staff on the investigational plan, which includes, but is not limited to, 
confidentiality, consenting process, enrollment, device accountability, study 
deviations, subject testing, product training, adverse event reporting, data 
collection, and study documentation.  In addition, the implanting surgeon 
will rec eive training in how to implant the Argus II system.  
13.1.[ADDRESS_589534]/device inventory control.  
All investigative sites will  be monitored for deviations related to protocol test 
procedures, exams, missed or out of window visits and subject 
noncompliance with study requirements. If a significant deviation/violation 
from the protocol is noted such as Inclusion/Exclusion violation , consent 
violation, or system misuse, the investigator must notify the Sponsor and the IRB immediately so that appropriate action can be taken.  If the 
investigator fails to implement the corrective action, the Sponsor may cease 
shipment of supplies, disc ontinue the investigation and/or notify the 
appropriate agencies.   
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 59 of 89 
Second Sight Medical Products, Inc.   Company Confidential  13.1.4 Site Closure  
Site/Study Closure Visit will focus on device inventory/reconciliation, 
adequacy of space for retention of study records, re -verification that the 
investigator study file cont ains all appropriate documentation, and 
verification that the investigator’s final study report is in progress.  
13.[ADDRESS_589535] be maintained at each study center . The 
number of devices delivered to and/or returned to SSMP and assigned to 
individual subjects by [CONTACT_461096].  Any accountability 
discrepancy at the end of the study needs to be explained in writing by [CONTACT_3786].  
13.[ADDRESS_589536] assessment are to be 
documented on the case report form provided for that purpose.  
14 Adverse Events  
Adverse Events (AE) are to be monitored from the t ime of enrollment 
through the last follow -up visit.   
An adverse event  is defined as any undesirable clinical occurrence in a 
subject whether it is considered system related or not.  This definition 
includes events occurring during surgery or the follow -up period.  Events 
may be:  
1. Observed or volunteered problems  
2. Physical signs and symptoms  
3. Medical condition(s) which occurs during the study, having been 
absent at baseline  
4. Medical condition(s) present at baseline, which appear to worsen 
during the study  
Exclu ded from the definition of adverse event are normal post -operative 
occurrences (e.g. inflammation, pain, etc.) that are routinely observed and 
managed medically.  Post -operative occurrences that are more severe than 
those normally observed would be conside red adverse events.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589537] be on a separate form, regardless of whether one event may be 
secondary to another.  
The following data are required for each AE:  
1. Repor table term (name [CONTACT_461112])  
2. Seriousness and reason for being serious.  
Serious Adverse Event Definition –  [LOCATION_002]  
A Serious Adverse Event (SAE)  for subjects enrolled in the US is 
defined as one that causes/is any one of the following:  
• death  
• life threa tening  
• permanent impairment of a body function or permanent damage 
to body structure  
• necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage 
to a body structure  
Permanent  means irreversible impa irment or damage to a body 
structure or function, excluding trivial impairment or damage.  
3. Relatedness to the subject’s disease, a procedure or the system.  Some adverse events may be unrelated.  Relatedness is based on 
likelihood of the causal relationship  
4. Anticipated (anticipated or AEs are listed in section 14.1.1 of the 
protocol). All others are ‘unanticipated’  
5. Start and resolution dates  
6. Description of the event, commentary on interventions (actions, 
procedures, medications) and outcomes  
AE forms are to be completed at the time of the event regardless of all data 
being available.  In cases where not all data are available, follow -up and 
final AE forms are to be completed as significant new data become available and when the e vent resolves.  
The need to capture adverse event s is not dependent upon whether or not 
the clinical event is associated with the use of the study product.  
All adverse event s occurring during the course of the study will be followed 
through to their resolut ion, even if this extends the subject’s participation 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 61 of 89 
Second Sight Medical Products, Inc.   Company Confidential  beyond the normal end of the study (i.e. 36 months).  If an AE is unresolved 
at the subject’s final study visit, the investigator should continue to follow 
and treat the adverse event as is clinically indicated, and report the follow -
up information on an adverse event form.   
14.1.1 Anticipated Adverse Events  
1. Infection  
• If an infection is presumed, attempt to confirm with microbiological 
testing  
2. Inflammation is not an AE if it is < Kimura class 2 and lasts for <  1 
month unless it raised IOP above 30mmHg.  
3. Hypopyon  
4. Hyphema is an AE if it:  
• Occurs in the immediate post -operative period and lasts > [ADDRESS_589538] surgery OR  
• Occurs later than one month post surgery , is mild (or worse) and 
lasts > 1 month OR  
• Is ‘8-ball h yphema’ OR  
• Causes high IOP (>30 mmHg).  
5. Vitreous hemorrhage is an AE if it:  
• Occurs in the immediate post operative period and lasts > one 
month post surgery OR  
• Occurs later than one month post surgery, is mild (or worse) and lasts ≥ 1 month  OR  
• Obscures the  view of the retinas such that ultrasound is needed to 
assess OR  
• Leads to IOP >30mmHg  
6. Retinal Folds are AEs if the affect the array placement or the tack.  
7. Vascular Congestion/Occlusion  
8. Cystoid Macular Edema/Choroidal Hemorrhage  
9. Conjunctival Erosion is an  AE if there is device exposure.  
10. Suture irritation is an AE if it requires surgical intervention.  
11. Scleral Erosion  
12. Choroidal detachment is an AE if –   
• It is ≥to 4 disc diameters OR  
• It displaces the array OR  
• Choroidals are ‘kissing’ OR  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 62 of 89 
Second Sight Medical Products, Inc.   Company Confidential  • It lasts for longer than 1 month OR  
• It is associated with a flat anterior chamber.  
13. Conjunctival congestion is an AE if it:  
• Occurs in the immediate post -operative period (within [ADDRESS_589539] -
operative) and lasts > 1 month OR  
• Occurs later than one month post surgery, is mild (or worse) and 
lasts > 1 month.  
14. Scleral Perforation – unintended perforation of the sclera  
15. Scar or fibrosis formation, including epi[INVESTIGATOR_43691]  
16. Ocular fibrin (anterior or vitreous) is an AE if it  
• Occurs in the immediate post -operative  period   and lasts >1month 
post surgery OR  
• Occurs later than one month post surgery, is mild (or worse) and 
lasts > 1 month  OR 
• Obscures the view of the retina  
• Raises IOP above 30mmHg.  
17. Retinal Tear or retinal break is an AE  
18. Retinal Detachment should be classified as:  
• Rhegmatogenous  (AE) OR  
• Subretinal fluid  
o Subclinical - ≤1 disc diameter and well demarcated is not an 
AE. 
o Clinical - >1 disc diameter  is an AE classified as either 
rhegmatogenous or tractional  
19. Retinal edema   
20. Retinal/subretinal hemorrhage is an AE only if it causes dislocation of the array.  
21. Cataract  
22. Corneal Opacity is an AE if it:  
• Covers the visual axis OR  
• Is infectious in nature.  
23. Corneal degeneration 
24. Corne al vascularization is an AE if it covers the visual axis.  
25. Corneal epi[INVESTIGATOR_461057] > [ADDRESS_589540]- surgery.  
26. Iris/Pupil changes are AEs if they  
• Lead to atrophy associated with significant functional or structural 
defects of the iris OR  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 63 of 89 
Second Sight Medical Products, Inc.   Company Confidential  • Lead to high IOP.  
27. Increased intra- ocular pressure (IOP)  
• Intra-ocular pressure increase more than 10 mmHg above baseline 
or intraocular pressure greater than 30 mmHg  
28. Hypotony (<5mmHg) is an AE if it  
• Persists  for > 2weeks OR  
• Is associated with kissing choroidals OR  
• Is associated with a flat anterior chamber.  
29. Ptosis  
30. Ocular pain or discomfort in the implanted eye  
31. Disturbed/difficult eye movement 
32. Dry eye  
33. Extrusion of band   
34. Intrusion of band  
35. Dislodgement of human sclera or equivalent allograft  
36. Electric Sh ock 
37. Migration of array  
38. Loosening/extrusion of device  
39. Increase in photophobia  
40. Side effects of medications and/or interactions with concurrent 
mediations and underlying medical conditions  
41. Respi[INVESTIGATOR_1399] – fail to wean from ventilator post- surgically  
42. Blood loss requiring active intervention such as transfusion  
43. Allergic reaction to anesthesia  
44. Loss of light perception  in eyes having pre -operative light perception  
The following are not AEs:  
• Corneal dryness  
• Descemets Folds  
• Retinal pi[INVESTIGATOR_461058] -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589541] is provided as general guidance but is not intended to be 
inclusive.   
Neurologic  
• Depression  
• Degeneration of cognition  
• Vertigo  
Cardiov ascular  
• Stroke/Transient Ischemic Attack  
• Cardiac arrhythmia  
• Cardiac arrest  
• Hypertension  
Musculo -Skeletal  
• Arthritis  
• Fracture  
• Gout 
Gastro -Intestinal  
• Ulcer 
• Mesenteric ischemia  
Endocrine  
• Diabetes  
• Thyroid disorders  
• Hormonal changes  
Systemic  
• Infection unrelated to the implant site.  
Mobility  
• Falls 
• Bumps  
• Minor injury  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589542] be done by [CONTACT_461097]/email ing or faxing the completed Adverse Event Form to the 
address below. In addition, the Sponsor recommends any such adverse 
events also be reported to the Institutional Review Board within ten working 
days of learning of the event or in accordance with the I RB terms of 
approval.  
 
Second Sight Medical Products  
Attn: Clinical Affairs  
[ADDRESS_589543], Building 3  
Sylmar, CA [ZIP_CODE]  
eFax:  +1 -[PHONE_9645]  
Scan and email to:  safety@2 -sight.com  
Phone:  +1 -[PHONE_9646]  
 
The sponsor and investigator shall imm ediately conduct an evaluation of any 
unanticipated, serious, system related adverse events.  A report of the 
results of such evaluation shall be submitted to FDA and to all reviewing Institutional Review Boards/Ethics Committees and all participating 
investigators within [ADDRESS_589544]’s subsequent medical course must be 
submitted to the study Sponsor until the event has subsided or, in case of 
permanent i mpairment, until the event stabilizes and the overall clinical 
outcome has been ascertained.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 66 of 89 
Second Sight Medical Products, Inc.   Company Confidential  14.2.2 Serious Adverse Events  
Serious Adverse Events should also be reported immediately to the Sponsor 
and to the IRB in compliance with the terms of study approval, regardless of 
system relatedness or if they are anticipated.  
14.2.3 Other Adverse Events Requiring Immediate Notification  
The following events should also be reported immediately to the Sponsor, 
regardless of their system relatedness or if they are anticipated:  
• Endophthalmitis  
• Rhegmatogenous retinal detachment requiring laser treatment or 
surgical intervention to repair  
• Hypotony requiring surgical intervention to treat  
14.2.4 Other Adverse Events  
All other adverse events will be documented in annual reports.  
14.3  Independent Med ical Safety Monitor  
An Independent Medial Safety Monitor (IMSM) has been appointed to 
oversee this study. The IMSM is independent of the study and has no real or 
apparent conflict of interest.  The IMSM is responsible for:  
• Reviewing individual serious adve rse events (SAEs) submitted by [CONTACT_461098]  
• Suggesting protocol modifications to prevent the occurrence of 
particular adverse events  
• Serving as a resource to the clinical investigators for advice about management of SAEs  
• Preparing regular reports concerning AEs.  Such reports will be submitted on a regular basis (at least) once per year.  
In the event of unanticipated SAEs or an unduly high rate of AEs, the 
Medical Safety Monitor will promptly contact [CONTACT_461099].  
15 Device Failures and Malfunctions  
All device failures and malfunctions are reported to the Sponsor via the complaint handling process, and the investigational de vice is returned to 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 67 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Sponsor for analysis if necessary.  The final report on the study results will 
include information on device failures and malfunctions.  Instructions for 
returning the investigational device will be provided by [CONTACT_461095].  
16 Ethical Con siderations  
16.1  Declaration of Helsinki  
The study will be performed in accordance with the relevant parts of the ICH 
Guidelines for Good Clinical Practices, the Declaration of Helsinki and the 
[LOCATION_002] Code of Federal Regulations.  
16.2  Ethics Committee/Institutional Review Board  
It is the Investigators’ responsibility to obtain and maintain written approval of the final study protocol, including the Informed Consent, from the 
appropriate Institutional Review Board/Ethics Committee.  It is also the 
Investigators ’ responsibility to notify that body about any amendments to 
these documents.  A copy of the written approval and the approved versions of the documents and a list of the Institutional Review Board/Ethics 
Committee members, their titles and occupations mus t be forwarded to the 
responsible study personnel at Second Sight Medical Products prior to first 
device shipment.  The written approval must identify the study and 
document the date of review.  
The Investigators must file all correspondence with the Instit utional Review 
Board/Ethics Committee and forward copi[INVESTIGATOR_461059].  
16.[ADDRESS_589545]/Ethics Committee as quick ly as possible after the epi[INVESTIGATOR_1865], in any 
event no later than [ADDRESS_589546] be informed about their right to withdraw from 
the study at any time and for any reason without sanction, penalty, or loss 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589547]/Ethics Committee  procedures be fore implementation.  
Following approval, the protocol amendment(s) will be distributed to all protocol recipi[INVESTIGATOR_461060].  
[ADDRESS_589548]- Approval Phase of the 
Study  
Expected date  of study initiation:  The post -approval phase of this study 
will begin in May 2013, following FDA approval of Second Sight’s 
Humanitarian Device Exemption (HDE) application for the Argus II Retinal 
Prosthesis System and IRB approval of the protocol at the  participating sites.  
Expected monthly number of study sites with IRB approvals:  Second 
Sight anticipates that all sites who enrolled subjects in the investigational 
phase of the study will continue to participate in the post -approval phase of 
the study.  
Expected number o f subjects enrolled per month:  Enrollment in the 
study is complete.  All subjects have been enrolled in the study during the investigational phase of the study.    
Expected date of study follow up completion: S tudy follow -up will be 
comple ted by [CONTACT_37112] 2019 (taking into account the allowable follow -up 
window) . 
Expected date for Final Report submission:  Assuming all follow -up has 
been completed by [CONTACT_37112] 2019, the final report will be submitted to the FDA by [CONTACT_36466] 2020.   
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 69 of 89 
Second Sight Medical Products, Inc.   Company Confidential  17.2  Study Reporting  Schedule  
Data collected in this study prior to Humanitarian Device Exemption (HDE) 
approval ha ve been reported to the FDA in the HDE application.  Data 
reported after the FDA has approved the HDE application will be reported to 
the FDA as part of the post -approval reporting process.   
In the post -approval phase of the study, the study sponsor will prepare the 
following reports for the FDA.  Copi[INVESTIGATOR_461061].  Copi[INVESTIGATOR_461062].  
• Routine Progress Reports :  Progress reports, which report the number 
of sites participating in the study, the number of subjects still enrolled 
in the study, and the rates of adverse events will be provided at the 
following intervals from the date of HDE approval : 
o 6 Months  
o 1 Year 
o 1.5 Years  
o 2 Years  
o Annually thereafter until the study is complete  
 
• Final Clinical Report:  A final clinical report, reporting all safety and 
benefit data, will be prepared once  all subjects have completed [ADDRESS_589549] be archived: the Investigator’s File 
containing all required Good Clinical Practice documents, including signed 
Informed Consent forms and subject -related materials, Case Report Forms 
and electronic records.   
In general, documents related to the clinical trial must be retained for at 
least 2 years ([LOCATION_003]) after its completion or regulatory approval.   Refer to the 
Clinical Trial Agreement for the record retention period for your site.  
17.4  Criteria for Terminating the Entire Study  
Sponsor reserves the right to termi nate the study but intends only to 
exercise this right for valid scientific or administrative reasons and reasons 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 70 of 89 
Second Sight Medical Products, Inc.   Company Confidential  related to protection of subjects.  Investigators and associated Institutional 
Review Boards will be notified in writing in the event of termination.  
Possible reasons for study termination include:  
• The discovery of an unexpected, significant, or unacceptable risk to the 
subjects enrolled in the study.  
• A decision on the part of Sponsor to suspend or discontinue development of the device.  
17.[ADDRESS_589550] to terminate the study at an 
investigational site if the site has severe protocol violations without any 
justification or adequate corrective action or if the center fails to adequately 
staff the study.   
Likewise, a principal investigator [INVESTIGATOR_461063] s tudy at his/her 
institution.  This decision must be followed by [CONTACT_461100], stating the reasons for termination.  
 
17.[ADDRESS_589551] of clinical research studies. These responsibilities and 
commitments are listed in Appendix A.  
 
17.7  Investigator Qualifications/Responsibilities 
Each Investigator must be qualified to participate in the study and agree to 
meet the responsibilities detailed in the Investigator Agreement (CP -003-
008).  
18 Publication Policy  
Refer the Procedures and Operations Manual for the complete publication 
policy.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589552]/Ethics Committee  approval 
of the protocol and Investigators Agreement will be completed prior to treatment at an investigational site.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 72 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Appendix B - Clinical Risk/Benefit Assessment  
 
1. Surgical Risks  
The subjects’ risks may involve st andard surgical risks resulting from the use 
of general anesthesia, steroids and antibiotics, use of conscious sedation, 
surgical related equipment and device implant.  The common surgical risks 
for vitreo- retinal procedures have been evaluated and are sho wn below:37 
 
Complication  Incidence (95% CI)  
Chest Pain  0.48 (0.06 – 1.72)  
Urinary Retention  0.96 (0.26 – 2.43)  
Myocardial Infarction  0.24 (0.01 – 1.33)  
Pulmonary Embolism  0.48 (0.06 – 1.72)  
Deep vein 
Thrombosis  0.48 (0.06 – 1.72)  
Other risks associat ed with general surgery include:  
• Respi[INVESTIGATOR_1399]  
• Blood loss greater than anticipated  
• Infection of operative site  
• Systemic infection  
• Hospi[INVESTIGATOR_461064]  
• Allergic reaction to anesthesia  
Some subjects may require clear corneal phacoemu lsification at the start of 
the implant procedure to remove the lens.  The incidence of adverse events associated with clear corneal phacoemulsification is very low, and a high 
volume cataract surgeon typi[INVESTIGATOR_461065] a rate of adverse events of 
approximately 0.1% for this procedure. The adverse events can range from posterior capsular tear to cortical drop in vitreous, or vitreous prolapse. All 
these adverse events can be successfully managed in the operative setting, 
since associated vitrectomy is being  performed at the same time.  
If a subject has a small eye, a canthotomy may be performed to help fit the implant in the orbit.  A careful canthotomy, followed by [CONTACT_461101].  Possible side effects of 
canthotomy include improper apposition of the eyelids, tearing, and chronic 
irritation at the lid margin.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589553] has an epi[INVESTIGATOR_461066], this membrane may be gently peeled off the surface of the retina, 
usually with forceps.  Possible adverse events associated with this procedure 
include accidental tearing of the retina, improper removal of the membrane causing re -proliferation of the membrane, and macular hole if the membrane 
covers the macular area.  
During the clinical feasibility study of the Argus 16, there were no surgery -
related adverse events in the six subjects implanted.
38  The implantation 
surgery for the Argus II is anticipated to be approximately three hours (five 
hours shorter than the Argus 16) and should present a lower risk for the 
surgical procedure.  In addition, the Argus II does not require implantation 
in the skull, again reducing the risks for the implantation procedure.  
2. Study Procedure Risks  
2.1. Retinal Photography and Optical Coherence Tomography  
Retinal photography and optical coherence tomography (OCT) are standard 
non-invasive diagnostic tests used routinely.  Possible adverse reactions may 
arise from the pupil dilation and include blood pressure changes and other cardiovascular reactions parti cularly in elderly subjects.
39,[ADDRESS_589554] 
likely adverse reactions to the dye, occurring in five to ten percent of 
subjects.42  In rare cases (<0.1%), anaphylactic shock may occur.43,44,[ADDRESS_589555] undergone multiple eye examinations using such dyes and thus the risk 
of a reaction du ring the study is remote.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589556] scans will be performed with the system off.  
2.5. Orientation and Mobility Testing  
During Orientation and Mobility (O&M) testing, subjects will be asked to walk 
a simple course without any obstac les in their way while closely supervised.  
During this testing the subjects may become disoriented with an elevated risk of bumpi[INVESTIGATOR_461067].  
3. Device -Related Risks  
Adverse events specifically associated with the use of the Argus II System may occur. These may include transient electric shock,  facial nerve 
stimulation and/or pain.  In addition, excessive heating of the external equipment may cause burn to the user.    
The Argus II Retinal Implant System may unexpectedly stop functioning. The cause of failure may include electrical shorts, and/or interconnect 
failure.  As a result of such a failure, explant may be required.  
3.1. Related to Sterility  
The surgical procedure and/or the Argus II implant may introduce sources of infection into the operative region.  To minimize the risk of infection, the 
Argus II implant is  sterilized to a sterility assurance level (SAL) of [ADDRESS_589557] -operative antibiotic 
regimen of the hospi[INVESTIGATOR_307].  Sustained infection may result in explant of the 
Argus II implant, removal of the eye, sepsis or death.  
The Argus II implant is sterilized using ethylene oxide (EtO).  High levels of EtO residuals are  known to be toxic in the eye.  Testing has been performed 
to demonstrate that the ethylene oxide (EtO) residuals present on the device after sterilization are below acceptable safety limits for this type of device.   
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589558] ant of the Argus II implant.  
3.3. Related to Cleanliness  
The Argus II implant may carry pyrogens and other contaminants, which 
may result in fibrin proliferation within the eye, fever and corneal opacity.  
The Argus II is periodically tested to assure that biobu rden is within required 
levels . 
3.4. Related to Sclerotomy and Vitrectomy  
Preparation of the eye to receive the Argus II implant requires multiple 
sclerotomy sites followed by [CONTACT_430343].  The surgical removal of 
the vitreous has a risk of retinal de tachment of approximately 4%, 46,47,48,49 
endophthalmitis of 0.05% and a risk of sympathetic ophthalmia of 0.1%.50   
In addition, vitrectomy may result in hyphema/vitreous hemorrhage, suprachoroidal hemorrhage, cystoid macular edema, or changes to 
intraocular p ressure.  
3.5. Related to the Extra -ocular Case and Scleral Band  
Implantation of the Argus II requires the placement of a scleral band upon 
which the case and internal coil ride.  Potential complications following band 
placement include band infection, endophthalmitis, scleral erosion and band extrusion.  In a series of 19 subjects with primary scleral band placement, 
Arroyo, et al. found no occurrence of band infection, endophthalmitis, scleral 
erosion or band extrusion.
51 
In two histopathologically examined cas es, D’Hermies, et al. found the 
scleral bands well encapsulated with changes to the scleral curvature and 
thickness, with implant durations of 60 and 161 months.52  The changes 
noted did not result in band infection, endophthalmitis or band extrusion.  
Additional potential risks of the scleral band and case are increased intra-
ocular pressure, scleral perforation, eye -movement disruption and ptosis, 
ocular pain and discomfort, conjunctival or scleral erosion, retinal tear and disrupted ocular lubrication resu lting in dryness and corneal erosion or 
vascularization.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589559] to fibrovascular proliferation and scar formation.  The proliferative growth around the tack 
could cause epi[INVESTIGATOR_461068], potentially leading to proliferative retinopathy (PVR). 
Studies as short  a two months and as long as 2.[ADDRESS_589560] and that retinal tissue was normal within 
one millimeter of the tacks.57 
In clinical practice, Abrams, et al 58 reported 50/53 (94%) of tacks 
implanted remained stable over [ADDRESS_589561] äjrvi 59 reported that 12/13 (92%) tacks were in place after 
120 months.  
Based on the above, the risk of tack dislodgement and proliferation leading 
to detachment is small.   
3.7. Electrode Array/Cable /Electronics Package  
The electrode arra y is connected to the extra -ocular case via a polyimide 
cable, passing through a sclerotomy.  The retinal tack holds the array in place.   
There is a risk of a comparatively long recovery period from the original 
sclerotomy procedure and of conjunctival er osion in the area over the 
electronics package .  In the Argus 16 clinical study, only two subjects (2/6, 
33%) had conjunctival erosion requiring surgical intervention.
38  The smaller 
size and increased flexibil ity of the cable for the Argus II will reduce the risk 
of conjunctival erosion.  However, the presence of the transcleral cable may 
predispose subjects to a leak at this sclerotomy site which could cause low 
intraocular pressure.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 77 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Placement of the array may  result in retinal touching, leading to retinal 
damage, break, or detachment.  In addition, the retinal structure under the 
array may be damaged during the implant procedure, by [CONTACT_7419]- term pressure 
exerted by [CONTACT_461102]/twisting  of array across 
the retina.  Such damage may result in retinal break and/or detachment.  In 
the Argus [ADDRESS_589562] -mortem 
histopathological analysis of 22 temporal bones and one brain stem from 13 cochlear implant subjects and repor ted, “Results of analysis suggested that 
ganglion cells were the responding elements to this implant and that useful auditory sensation could result from as few as 10 percent of the normal 
number of ganglion cells.”  
In addition, the subjects for this feasi bility study are the most advanced in 
the disease.  Edwards, et.al. and Gartner, et.al. indicate that advanced retinitis pi[INVESTIGATOR_461069] a protective effect against possible retinal 
detachment.
61,[ADDRESS_589563] critical to the continued operation of 
the Ar gus II.  Excessive heating of biological tissues denatures proteins 
within the cellular structure and kills living cells.  Pi[INVESTIGATOR_461070], et al. showed that no retinal tissue damage occurred when the temperature of the vitreous 
increased by 5 ° C, with 2 ° C at the retina, using direct heating with 
500mW.
63 
In vitro testing of the Argus II has shown an extra -ocular temperature rise 
of less than 2 ° C.  This small temperature increase indicates that heating 
damage to ocular structures is unlikely to occur with th e current design 
which limits transmitted power to a nominal value of 100mW.  
In the unlikely event of heating damage, potential adverse events are cellular death, retinal detachment and loss of ability to elicit percepts.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 78 of 89 
Second Sight Medical Products, Inc.   Company Confidential  3.9. Related to the Explant Procedure  
The explant procedure has the same risks as the implant procedure, array 
placement and retinal tacking.  In addition, the removal of scleral bands has 
an 8.3% risk of retinal damage. [ADDRESS_589564] basis.  
It is possible  that the revision surgery may not achieve the desired 
improvement or may worsen the system performance.  In addition, it is 
possible that the implant may become damaged during the revision surgery, requiring further surgical intervention to remove or repa ir it. Guidance for 
avoiding damage to the device during revision surgery is provided in the Clinician’s Manual.  
3.11.   Long -Term Radiofrequency Transmission Risks  
With radio -frequency transmitter coils, there is a concern about the risk to 
the subject related t o their long -term use.  The FDA has approved, as safe 
and effective, a number of implanted nerve stimulators that are powered by 
[CONTACT_186355]-frequency coils.  There is a substantial history dating back to the 
1960s of using radio -frequency to power various impla nted nerve 
stimulators.  Such power transmission obviates the need for implanting 
bulky batteries (and the need for surgery to replace batteries).  The history of these devices in subjects, which includes cochlear implants and a class of 
spi[INVESTIGATOR_461071], demonstrates uniform safety and reliability of the 
radio-frequency links.  
Furthermore, the radio -frequency transmission in the megahertz frequency 
range would be too rapid to effect any nerve stimulation; the only 
established effect would be tissue heating when very high powers are 
applied.  With this in mind, several organizations have established standards 
for safe levels of energy deposition.  The specific absorption rate (SAR) is a 
measure of the rate of energy absorbed by (dissipated in) an incr emental 
mass contained in a volume element of dielectric materials such as biological tissues.  The table below lists several organizations that have established a 
recommended SAR level for this type of device.   
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 79 of 89 
Second Sight Medical Products, Inc.   Company Confidential  3.11.1.  Radiofrequency Transmission Standards  
Organ ization  SAR Level  
Federal Communications Commission 
(FCC) Office of Engineering and 
Technology (OET) 65  <8 W/kg (during occupational or controlled partial -body exposure)  
Institute of Electrical and Electronics Engineers (IEEE)
 66  <8 W/kg (during occupati onal or 
controlled partial -body exposure)  
<1.6 W/kg (in uncontrolled 
environments)  
International Commission on Non -
Ionizing Radiation Protection (ICNIRP) 
67  <10 W/kg (during occupational or 
controlled localized head or trunk 
exposure)  
 
Lazzi et.al. have modeled the thermal elevation due to induced electric and 
magnetic fields and have found that power dissipation under worst case 
conditions for a retinal implant are 0.6C in the eye and 0.2C in the retina.[ADDRESS_589565] automatic 
safety checks to ensure that all delivered stimulation is charge balanced.  
3.12.1.  Risks of High Stimulation 
One of the risks of electrical stimulation is that high levels of stimulation for 
prolonged periods of time can result in da mage to the electrodes, to the 
tissue being stimulated and/or to the retina.  To protect against this, the Argus [ADDRESS_589566].  The 
maxim um allowable chronic stimulation charge is 350 μC/cm
2.   
The Argus II implant has been tested to demonstrate that the electrodes can withstand this maximum stimulation level for the duration of use anticipated 
in this study.  
McCreery, et al. studied the risk of neural damage related to peripheral neural stimulation.
69  In their study, they found that at lower frequencies 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 80 of 89 
Second Sight Medical Products, Inc.   Company Confidential  (<50Hz), continuous stimulation at up to 1600 μc/cm2 induced little or no 
neural injury using electrodes of a similar size to that of the Argus II.   In 
addition, they concluded that even when nerves must be stimulated at 
higher frequency it should be possible to safely stimulate the nerve 
continuously at an amplitude that fully recruits all the motor -neuron axons in 
the nerve (i.e. it is poss ible to activate the nerve and reach therapeutic 
effect before causing damage).   
Weiland, et al.70  showed no histopathological changes with up to 120 days 
of stimulation in the canine model at current levels of 180 µA and 90 µ A and 
Rizzo, et al.71 found no  clinical or histological damage using charge densities 
of up to 1000 μC/cm2 acutely in humans.  
In the event that physiologic responses cannot be achieved at 350 μC/cm2, 
it may be necessary to temporarily exceed the safe chronic limit (i.e. 
stimulate up to  1000 μC/cm2).  If it is necessary to exceed the 350 μC/cm2 
limit, this would only occur for brief periods of time (i.e. not more than 4 
hours at any one time in the clinic).  The risk of increasing the charge 
density limit is that damage could occur to the electrodes or to the tissue.  
In physiologic saline, electrolysis of water and bubbling occurs (gassing 
limit) above 2000  μC/cm2 with platinum electrodes, therefore stimulation at 
1000 μC/cm2 should be well below the limit for the electrode material.  In  
addition to Rizzo’s results, experimental data from acute experiments 
performed at Johns Hopkins showed acute stimulation in patients with 
injected charge as high as 4900 μC/cm2/phase (with platinum electrodes) 
resulted in no adverse events and no histopa thologic abnormalities.  
Based on these results, the potential for injury related to the maximum 
stimulation current allowable by [CONTACT_461103].  
  
3.13.  Risks of Device Degradation  
All implantable devices are susceptible to degradation over time due to the harsh environment of the body.  The Argus II implant has been tested to 
demonstrate that it can survive (i.e. maintain hermeticity and functionality) for the duration of this study.  In the remote event that the device did lose 
hermeticity or functiona lity, it may require explantation.   
3.14.  Risks of System Use While Mobile  
Subjects are allowed to use the system while mobile as long as they do not 
use the system as their only mobility aid.  When using the system while 
mobile, they may become disoriented leading to an elevated risk of bumpi[INVESTIGATOR_461072].  A failure of the system while mobile could also 
cause these events.  In addition, subjects may become entangled in the 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589567] from VPU to reduce the likelihood of an injury occurring.  By [CONTACT_461104], the likelihood of 
these events occurring should be minimal.  
4. General Population Risks  
This section lists the general life -risks associated with our targeted 
population.  It is not anticipated that the Argus II System will increase the frequency of these risks.  
4.1. General Risks  
Neurologic  
• Depression  
• Degeneration or change in cognition  
• Vertigo  
Cardiovascular  
• Stroke/Transient Is chemic Attack  
• Cardiac arrhythmia  
• Cardiac arrest  
Musculo -Skeletal  
• Arthritis  
• Fracture  
• General musculo -skeletal degeneration  
Gastro -Intestinal  
• Ulcer 
• Mesenteric ischemia  
Systemic  
• Infection unrelated to the implant site.  
• Carcinoma  
 
4.2. Depression  
Depression is comm only associated with vision loss due  to the loss of a 
sensory organ and the social isolation.
 72,73  Functional ability is inversely 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589568] risk 
for depression.  Literature would indicate, however, that the provision of 
percepts may reduce the incidence in this population.  
4.3. Falls and Minor Injuries  
Falls and minor injuries are a serious concern for aging subjects.  Nordell in 
a retrospective survey found that 30% of subjects over the age of [ADDRESS_589569]’s acuity decreases.  Tobis 
et.al. studied non -impaired, blind and deaf subjects for the propensity to 
fall.77  They found that the rate of falling in blind subjects (20/200 –  no light 
perception) was twice that of non -impair ed subjects (53.4% vs. 26.7%, p = 
0.003).  
5. Potential Benefits  
The potential benefits of the Argus II System are under study in the 
feasibility  human trial stage and as such cannot be numerically evaluated.  
Evidence from the rate of increasing depression, i solation, falls and minor 
injuries in blind subjects would suggest that the use of the Argus II System 
might:  
• allow subjects to have an increased interaction with their 
surroundings,  
• reduce the risk of injury by [CONTACT_461105], and  
• increase the quality of life of subjects  
 
6. Risk/Benefit Analysis  
The implantation and use of the Argus II System has a small risk of serious 
injury and many of the anticipated adverse events can be treated either 
non-invasively with minimally invasive surgery , although unforeseen risks 
may be identified during the course of study.  In addition, this feasibility 
study will enroll only subjects with minimal or no vision, reducing the risk to 
residual vision and the potential for retinal detachment.  The potentia l 
benefits to the subjects overall life quality, with greater independence and mobility outweigh the relatively minor risks from implantation and use.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 83 of 89 
Second Sight Medical Products, Inc.   Company Confidential  Appendix C - BIBLIOGRAPHY  
                                    
1 Humayun MS , de Juan E Jr , Dagnelie G , et al.  Visual Perception Elicited by 
[CONTACT_461106].  Arch Ophthalmol.  
1996;114(1):40- 6. 
2 Thomas BB , Arai S, Ikai Y , Qiu G , et.al.  Retinal transplants evaluated by 
[CONTACT_461107].  J 
Neurosci Methods.   2005 Aug 26.  
3 Greenburg RJ.  Visual Prostheses: A Review.  Neuromodulation.   
2000;3:161- 165. 
4 Dobelle WH.  Artificial Vision for the Blind by [CONTACT_461108] a Television 
Camera to the Visual Cortex.  ASAIO Jo urnal  2000;46:3- 9 
5 Humayun M.S., de Juan Jr. E., Dagnelie G., et.al.  Visual Perception Elicited 
by [CONTACT_461106].  Arch Ophthalmol.   
Volume 114, January 1996.  
6 Humayun M.S., de Juan Jr. E., Weiland J.D., et.al.  Patte rn electrical 
stimulation of the human retina.  Vision Research.   1999;39:2569-
2576.  
7 Weiland J.D., Humayun M.S., Dagnelie G., et.al.  Understanding the origin 
of visual percepts elicited by [CONTACT_461109].  
Graefe’s Arch Clin Exp Ophthalmol.   1999;237:1007- 1013.  
8 Rizzo JF, et al.  Acute Intraocular Stimulation in Normal and Blind Humans.  
Investigative Ophthalmology and Visual Science.  41(4):S102(532), 
March 15, 2000.  
9 Majji A.B., Humayun M.S., Weiland J.D., et.al.  Long -Term Histological and 
Electrophysiological Results of an Inactive Epi[INVESTIGATOR_461073].  Investigative Ophthalmology and Visual 
Science.  1999;Vol. 40. No. 9.  
10 D’Anna S.A., Humayun M.S., Weiland J.D., et.al.  Long -term 
biocompatibi lity of an epi- retinal electrode array implant.  1999 
Association for Research in Vision and Ophthalmology (ARVO) 
Conference.  
11 Walter P., Szurman P., Vobig M., et.al.  Successful Long -Term 
Implantation of Electrically Inactive Epi[INVESTIGATOR_461074].  Retina, The Journal of Retinal and Vitreous Diseases.  1999. Volume 19, Number 6.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589570] –operative evaluation in 
the selection of subjects for acute epi[INVESTIGATOR_461075].  2004 Association for Research in Vision a nd Ophthalmology (ARVO) 
Conference.  
14 Mahadevappa M, Weiland JD, Yanai D, et.al.  Correlation of electrical 
detection thresholds with electrode impedance in a retinal prosthetic implant.  2004 Association for Research in Vision and Ophthalmology 
(ARVO) Con ference.  
15 Yanai D, Weiland JD, Mahadevappa M, et.al. Performance of visual tasks 
using an epi[INVESTIGATOR_461076].  2004 Association for Research in Vision 
and Ophthalmology (ARVO) Conference.  
16 Humayun M, Yanai D, Greenberg RJ, et.al. Chronically Implanted  
Intraocular Retinal Prosthesis in Three Blind Subjects.  2004 Association for Research in Vision and Ophthalmology (ARVO) 
Conference.  
17 Weiland JD, Guven D, Fujii GY, et.al.  Morphometric Analysis of Chronic 
Electrically Stimulated Canine Retina.  2005 As sociation for Research 
in Vision and Ophthalmology (ARVO) Conference.  
18 Weisel JM, Freda R, Greenberg R, et.al.  Pupi[INVESTIGATOR_461077].  2005 Association for Research in Vision and Ophthalmology (ARVO) Confer ence.  
19 Kim LA, Winter T, Lam TT, et.al.  Retinal Prosthetic and Circadian 
Rhythms.  2005 Association for Research in Vision and Ophthalmology 
(ARVO) Conference. 
[ADDRESS_589571], Fujii GY, et.al.  Surgical Design Considerations for 
Implantation of Mo del 1 Retinal Prosthesis.  2005 Association for 
Research in Vision and Ophthalmology (ARVO) Conference.  
[ADDRESS_589572] With a Chronic 
Intraocul ar Retinal Prosthesis.  2005 Association for Research in Vision 
and Ophthalmology (ARVO) Conference.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 85 of 89 
Second Sight Medical Products, Inc.   Company Confidential                                                                                                                   
22 Freda R, Fujii G, Agrawal RJ, et.al. Epi[INVESTIGATOR_461078].  2005 Association for Research in Vision and Ophthalmology 
(ARVO) Conf erence.  
23 Humayun MS, Freda R, Fine I, et.al.  Implanted Intraocular Retinal 
Prosthesis in Six Blind Subjects.  2005 Association for Research in 
Vision and Ophthalmology (ARVO) Conference.  
24 Mahadevappa M, Weiland JD, Yanai D, et.al.  “Perceptual Thresholds and 
Electrode Impedance in 3 Retinal Prosthesis Subjects”.  IEEE Trans 
Neural Syst Rehabil Eng. 2005;13(2):201- 6. 
25 McMahon MJ, Fine I, Greenwald SH, et.al.  Electrode impedance as a 
predictor of electrode -retina proximity and perceptual threshold in a 
retinal prosthesis.  2006 Association for Research in Vision and 
Ophthalmology (ARVO) Conference. 
26 Humayun MS, Hopkins J, Greenwald SH, et.al.  Electrical effects and 
perceptual performance using a chronically implanted 16 -channel 
epi[INVESTIGATOR_461079].  2006 Association for Research 
in Vision and Ophthalmology (ARVO) Conference.  
27 Guyton AC. Textbook of Medical Physiology. 9th ed.  WB Suanders 
Company. 1996.  
28 Oyster CW.  The Human Eye: structure and function.  Sinauer Associates. 
1999.  
29 Campbell FW, Howell ER, Robson JG.  The appearance of grating with and 
without the fundamental Fourier component.  J Physiol .  1971 217:17-
18. 
30 Misajon R, Hawthorne G, Richardson J, et.al.  Vision and Quality of Life: 
The Development of a Utility Measure .  Invest Ophthalmol Vis Sci.   
2005;46:4007- 4015.  
[ADDRESS_589573], Baker FH, et.al.  Visual Disability Variables I: The 
importance and difficulty of activity goals for a sample of low -vision 
patients.  Arch Phys Med Rehab.   2005:86;946- 53. 
[ADDRESS_589574], Baker FH, et.al.  Visual Disability Variables II: The 
importance and difficulty of activity goals for a sample of low -vision 
patients.  Arch Phys Med Rehab.   2005:86;954- 67. 
[ADDRESS_589575], Turano KA, Stahl JW.  Traditional Measures of Mobility 
Performance and Retinitis Pi[INVESTIGATOR_1802].  Optom Vis Sci.  1998;75:525-
537. 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 86 of 89 
Second Sight Medical Products, Inc.   Company Confidential                                                                                                                   
34 Turano KA, Broman AT, Bandeen- [COMPANY_002] K, et al.  Association of Visual 
Field Loss and Mobility Performance in Older Adults: Salisbury Eye 
Evaluation Study.  Optom Vis Sci.  2004;81:298- 307. 
35 Edwards RS, Calder IG, Crews SJ.  Retinal detachment in retinitis 
pi[INVESTIGATOR_1802].  Trans Ophthalmol Soc.   1985:104:315- 318. 
36 Gartner S, et.al., Pathology of Retinitis Pi[INVESTIGATOR_1802].  Ophthalmology  
1982;89:1425- 32. 
37 McCannel CA, Nordlund JR, Bacon D, Perio perative morbidity and mortality 
associated with vitreo -retinal and ocular oncologic surgery performed 
under general anesthesia.  Trans Am Ophthalmic Soc   2003;101:209-
216. 
38 Argus 16 IDE Annual Progress Report, data on file.  Second Sight Medical 
Products . 
39 Phenylephrine Hydrocloride Ophthalmic Solution, 2.5% Product Insert. 
Alcon Laboratories Inc, Fort Worth, [LOCATION_007], [LOCATION_003].  
40 Fraunfelder FT, Meyer SM. Possible cardiovascular effects secondary to 
topi[INVESTIGATOR_117927] 2.5% phenylephrine.  Am J Ophthalmol . 1985 Mar 
15;99(3):362- 3. 
41 Dorfman LJ, Gaynon M, Ceranski J, et.al., Visual electrical evoked 
potentials: Evaluation of ocular injuries.  Neurology . 1987;37:123- 128. 
42 Watt WS. Fluorescein Angiogram. w ww.mdsupport.org/library/angio.html . 
43 Jennings BJ, Matthews DE, Adverse reactions during retinal fluorescein 
angiography. J Am Optom Assoc  1994;65(7):465- 71. 
44 Fineschi V, Monasterolo G, Rosi R, Turillazzi E, Fatal anaphylactic shock 
during a fluorescein angiography. Forensic Sci Int 1999;100(1- 2):137-
42. 
45 Hitosugi M, Omura K, Yokoyama T, el.al., An autopsy case of fatal 
anaphylactic shock following fluorescein angiography: a case report. 
Med Sci Law  2004;44(3):264- 5. 
46 Hurley M, EVS gives vitrectomy gre en light. EyeNet Magazine  May 2001.  
47 By[CONTACT_461110], Chu YK, Lee SC, et.al., Problems associated with the 25 -gause 
transconjunctival sutureless vitrectomy system during and after 
surgery.  Ophthalmologica  2006;220(4):259- 65. 
48 Rauber M, Mester U, Incidence and prophylaxis of retinal detachment 
following pars plana vitrectomy.  Ophthalmologe  2006; June 14.  
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 87 of 89 
Second Sight Medical Products, Inc.   Company Confidential                                                                                                                   
49 Schrey S, Krepler K, Wedrich A, Incidence of rhegmatogenous retinal 
detachment after vitrectomy in eyes of diabetic patients.  Retina  
2006;26(2)149- 52. 
50 Kilmartin DJ, Dick AD, Forrester JV, Sympathetic ophthalmia risk following 
vitrectomy: should we counsel patients? Br J Ophthalomol 
2000;84:448- 9. 
51 Arroyo JG, Postel EA, Stone T, et.al., A matched study of primary scleral 
buckle placement during repair of po sterior segment open globe 
injuries. Br J Ophthalmol 2003;87:75- 78. 
52 D’Hermies F, Korobelnik J, Capuot G, et.al., Encapsulation of scleral buckle 
materials: A study of sixty specimens. Ophthalmology  1998;105:1079-
1086.  
53 Ohira A, de Juan E, Tsai M, Long -term histologic and electrophysiologic 
evaluation of the alloy retinal tack.  Graefes Arch Clin Exp Ophthalmol  
1991;229(1):95- 8. 
54 Algvere P, Jahnberg P, Fibrovascular response to retinal tacks in the rabbit 
and monkey eye. Acta Ophthalmol (Copenh)  1990;68( 5):543 -8. 
55 Daus W, Volcker HE, Aexandridis E, Kasman B, Histopathology finding 
following retinal tack implantation.  Ophthalmologica  
1989;199(4):164- 4. 
56 Gerding H, Taner S, Benner FP, et.al., Successful long -term evaluation of 
intraocular titanium tacks for the mechanical stabilization of posterior segment ocular implants.  Mat. -wiss. U. Werkstofftech 2001;32:903-
913. 
57 Ohira A, de Juan E, Tsai M, Long -term histologic and electrophysiologic 
evaluation of the alloy retinal tack.  Graefes Arch Clin Exp Opht halmol  
1991;229(1):95- 8. 
58 Abrams GW, Williams GA, Neuwirth J, McDonald HR, Clinical results of 
titanium retinal tacks with pneumatic insertion.  Am J Ophthalmol   
1986;102(1):13- 9. 
[ADDRESS_589576] äjrvi TJ, Ter äsvirta ME, Retinal fixation of traumatic retinal 
detac hment with metallic tacks: A case report with 10 year’s follow -up.  
Retina  2001;21:54- 6. 
60 Linthicum FH, et.al. Cochlear implant histopathology.  Am J Otology  
1991;12:245- 311. 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page 88 of 89 
Second Sight Medical Products, Inc.   Company Confidential                                                                                                                   
61 Edwards RS, Calder IG, Crews SJ.  Retinal detachment in retinitis 
pi[INVESTIGATOR_1802].  Trans Ophthalmol Soc.   1985:104:315- 318. 
62 Gartner S, et.al., Pathology of Retinitis Pi[INVESTIGATOR_1802].  Ophthalmology  
1982;89:1425- 32. 
63 Pi[INVESTIGATOR_461080], Margaliy E, Chen SJ, et.al., Heat effects on the retina.  
Ophthalmic Surg Lasers Imaging  2003;34:114- 120. 
64 Deokule S, Reginald A, Callear A, Scleral buckle explant: the last decade. 
Eye 2003;17(6):697- 700. 
65 Bulletin 56 “Questions and Answers about Biological Effect and Potential 
Hazards of Radiofrequency Electromagnetic Fields”, Federal 
Communications Commiss ion (FCC) Office of Engineering and 
Technology (OET).  
[ADDRESS_589577] C95.1 “IEEE Standard for Safety Levels with Respect to Human 
Exposure to Radio Frequency Electromagnetic Fields, 3 KHz to 300 GHz”, Institute of Electrical and Electronics Engineers (IEEE).  
67 “Guidelines for Limiting Exposure to Time -Varying Electric, Magnetic, and 
Electromagnetic Fields (Up to 300 GHz)”, International Commission on Non-Ionizing Radiation Protection (ICNIRP).  
68 Lazzi G, DeMarco SC, Liu W, Computed SAR and Thermal Elevation in a 
0.25mm 2D Model of the Human Eye and Head in response to an 
Implanted Retinal Stimulator. Part II: Results .  IEEE Trans Antennas & 
Propagation  2003;51:2286- 2295.  
69 McCreery DB, Agnew WF, Yuen TGH, Bullara L, Charge density and charge 
per phase as cofacto rs in neuronal injury induced by [CONTACT_461111].  IEEE Trans on Biomed Eng  1990;37;996- 1001.  
70 Weiland JD, Fujii GY, Mech BV, et.al., Chronic electrical stimulation of the 
retina in RCD1 and normal dog. ARVO  2003 poster B740.  
71 Rizzo JF, Wyatt J, L owenstein J, et.al., Methods and perceptual thresholds 
for short -term electrical stimulation of human retina with 
microelectrode arrays. IOVS  2003;44:5355- 5361.  
72 Pearlman JT, Adams GL, Sloan SH [eds], Psychiatric Problems in 
Ophthalmology, Thomas Books, 1 977. 
73 Strougo Z, Badoux A, Duchanel D, Psycho -affective problems associated 
with retinitis pi[INVESTIGATOR_1802]. J Fr Ophthalmol  1997;20(2):111- 6. 
74 Ip SP, LeungYF, Mak WP, Depression in institutionalized older people with 
impaired vision. Int J Geriatr Psychiatry 2000;15(12):1120- 4. 
Extended Follow -Up of Ar gus™ II System Feasibility Protocol 
Revision O  
Page [ADDRESS_589578] of rehabilitation on 
depression among visually impaired older adults. Aging & Mental 
Health  2005;9(6):563- 570. 
76 Nordell E, Jarnlo G, Jets én C, et.al., Accidental falls and related fractu res 
in 65-74 year olds: A retrospective study of 332 patients. Acta Orthop 
Scand  2000;71:175 -179. 
77 Tobis JS, Block M, Steinhaus -Donham CA, et.al., Falling among the 
sensorially impaired elderly. Arch Phys Med Rehab 1990;71:144- 147. 